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ABSTRACT 
Huntington’s disease (HD) is a fatal neurodegenerative disease with progressive motor dysfunction, 
cognitive decline and psychiatric disturbances. HD is caused by a CAG repeat expansion in the 
huntingtin (IT15) gene, which encodes the huntingtin protein. Mutations in huntingtin cause 
accumulation of protein aggregates with subsequent cell death and loss of neurons in the striatum 
and cortex. The exact molecular mechanisms by which mutant huntingtin (mHTT) induces cell 
death are not completely understood.  
Huntingtin protein participates in many cellular functions such as protein trafficking, transcriptional 
regulation and apoptosis. Mutant protein is cleaved to form N-terminal fragments containing the 
first 100-150 residues including the polyglutamine repeats, which are thought to be the toxic species 
found in aggregates. Previous studies have shown that endoplasmic reticulum (ER) stress is 
involved in the early pathogenesis of HD. However, the precise mechanisms by which mHTT 
proteins cause ER stress are still unclear.  
The aim of this thesis was to elucidate the early pathological changes in HD. The specific goal was 
to study in more detail how ER stress, alterations in autophagy and ubiquitin proteasome system and 
oxidative stress trigger the disease and by which mechanisms. This thesis also aimed to identify 
novel therapeutic targets for early pathogenic changes in HD.  
The results showed that growth arrest and DNA damage inducible gene 34 (GADD34) plays an 
important role in cell protection and mediates cytoprotective autophagy via the mammalian target of 
rapamycin (mTOR) pathway in mHTT expressing cells. Modulation of GADD34 may thus prove 
useful in counteracting cell degeneration accompanying HD. 
Our results also showed that the sigma-1 receptor (Sig1R) agonist PRE084 increased levels of 
cellular antioxidants by affecting the NF-κB pathway that is reduced by expression of mHTT 
proteins. The Sig1R agonist increased cell survival and counteracted the deleterious effects caused 
by N-terminal mHTT proteins. Compounds that influence the Sig1R may have beneficial effects in 
models of HD, which warrants further studies.  
This thesis also shows that overexpression of ubiquitin-specific protease-14 (Usp14) reduces 
cellular aggregates in mHTT expressing cells mainly via the ubiquitin proteasome system. 
Overexpression of Usp14 was able to inhibit phosphorylation of inositol requiring enzyme 1 (IRE1) 
in mHTT expressing cells and to protect against cell degeneration and caspase-3 activation. These 
results show ER stress induced IRE1 activation is part of mHTT toxicity, which is inhibited by 
Usp14.  
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1 INTRODUCTION 
Huntington’s disease (HD) is the most common dominantly inherited neurodegenerative disorder, 
affecting 1 in 10,000 people of Western world. It leads to progressive motor dysfunction, cognitive 
decline, psychiatric disturbances and marked brain atrophy with loss of neurons, especially in 
caudate-putamen and the frontal lobes (van Dellen et al., 2005). The disease is caused by a CAG 
(encoding glutamine) repeat expansion in the first exon of the IT15 gene, resulting in the expression 
of mutant huntingtin (HTT) with greater than ~36 glutamines (Gil and Rego, 2008). 
Huntingtin protein (350kDa) is expressed in most tissues, including the nervous system (DiFiglia et 
al., 1995; The Huntington's Disease Collaborative Research Group, 1993). In neurons, HTT 
expression is localized to neuronal cell bodies, axons and dendrites with subcellular localization to 
vesicles and presynaptic terminal fibers and nerve-endings (DiFiglia et al., 1995). Mutation in HTT 
causes accumulation of intracellular and intranuclear protein aggregates. Mutant protein is cleaved 
to form N-terminal fragments containing the first 100-150 residues including the polyglutamine 
repeats, which are thought to be the toxic species found in aggregates (Ross and Tabrizi, 2011). 
Huntingtin protein participates in many cellular functions such as protein trafficking, transcriptional 
regulation and apoptosis (Ross and Tabrizi, 2011). HTT is a subject to many post-translational 
modifications, including proteolysis, phosphorylation and modification by ubiquitin and ubiquitin-
like proteins (Lu et al., 2013). 
HD is a complex disease and the mechanisms by which mHTT causes neuronal dysfunction and 
degeneration are not yet fully understood. Thus, it has been difficult to develop therapies that 
effectively target HD’s toxic effects. Huntingtin can interact with over 150 protein partners and, 
when mutated, interferes directly and indirectly with dozens of cellular pathways. Impaired 
ubiquitin-proteasome activity, defective autophagy-lysosomal function, transcriptional 
dysregulation, oxidative stress, apoptosis, mitochondrial and metabolic dysfunction, and abnormal 
protein-protein interaction have been shown to play important roles in the pathogenesis of HD 
(Anderson, 2011; Gil and Rego, 2008).  
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2 REVIEW OF THE LITERATURE 
2.1 Huntington’s disease 
Huntington’s disease (HD) is an inherited neurodegenerative disorder, also known as Huntington 
chorea. Its clinical features and pattern of familial transmission was first described by a young 
physician George Huntington in 1872 (Huntington, 1872; Huntington, 2003). But it was not until 
the end of next century, in 1993, that the actual HD gene mutation and cause of the disease was 
discovered by a multicenter consortium, organized by the Hereditary Disease Foundation (The 
Huntington's Disease Collaborative Research Group, 1993).  
Huntington’s disease is caused by a cytosine-adenine-guanine (CAG) nucleotide repeat expansion in 
Huntingtin (HTT, also known as the interesting transcript IT15) gene in chromosome 4. Mutation in 
HTT gene leads to an expanded polyglutamine (polyQ) stretch in the huntingtin (HTT) protein (The 
Huntington's Disease Collaborative Research Group, 1993). HD is inherited in an autosomal 
dominant manner, thus a child has a 50% chance of inheriting HD from a diseased parent (Myers et 
al., 1993). Individuals with Huntington's disease can become symptomatic at any time between the 
ages of 1 and 80 years, but in most cases the onset of the disease occurs in midlife, between the ages 
of 35 and 50 years. Patients with juvenile HD, defined as having disease onset before age 20, 
typically have a very large number of CAG repeats, usually greater than 55 (Foroud et al., 1999). 
The disease progresses over time and is invariably fatal 15–20 years after the onset of the first 
symptoms (Ross and Tabrizi, 2011; Walker, 2007). 
In addition to HD, there are eight other polyglutamine diseases: dentatorubral-pallidoluysian 
atrophy (DRPLA), spinal and bulbar muscular atrophy (SBMA) and the spinocerebellar ataxias 
(SCAs) 1, 2, 3, 6, 7 and 17. (Table 1.) These diseases have a striking genotype–phenotype 
correlation. Although the expected functions of the causative genes and the surrounding amino acids 
are quite different from each other, most of the diseases result from more than 40 polyQ repeats and 
share several common features, including neuronal dysfunction and loss in the central nervous 
system. Clinical features include ataxia and other movement disorders, loss of cognitive ability, and 
psychiatric disabilities (Marsh et al., 2009; Takahashi et al., 2010). 
Prevalence of HD is four to ten cases per 100 000 individuals in the western world (Ross and 
Tabrizi, 2011). Exceptions can be seen in areas where the population can be traced back to a few 
founders, such as Tasmania (Pridmore, 1990) and the area around Lake Maracaibo in Venezuela 
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Also 10-25% of HD patients exhibit diabetes mellitus (Farrer, 1985). As motor and cognitive 
deficits become severe, patients eventually die, usually from complications of falls, inanition, 
dysphagia, or aspiration. Typical latency from diagnosis to death is 20 years (Walker, 2007). 
 
2.1.1 Huntingtin 
Huntingtin (HTT) is a large (~350kDa) multidomain protein expressed in all human and mammalian 
cells, with the highest concentrations in the brain and testes. Moderate amounts of HTT are present 
in the liver, heart, and lungs. HTT is ubiquitously distributed in neurons, particularly in cell bodies 
and dendrites (DiFiglia et al., 1995). Within the cell, cytoplasmic HTT is associated with 
mitochondria, the Golgi apparatus, the endoplasmic reticulum, synaptic vesicles and several 
components of the cytoskeleton (Gil and Rego, 2008). To a lesser extent HTT is also present in the 
nucleus (Kegel et al., 2002).  
The role of the wild-type (wt) protein is still poorly understood but different studies have shown that 
it is engaged in many intracellular functions such as: protein trafficking, vesicle transport and 
anchoring to the cytoskeleton, clathrin-mediated endocytosis, postsynaptic signaling, transcriptional 
regulation and anti-apoptotic function (Gil and Rego, 2008).  
HTT is also suggested to be essential for normal embryonic development; knockout mutations that 
disrupt the promoter, exon 4 or exon 5 of the mouse HD gene homolog (Hdh) leads to complete 
inactivation of the gene and finally to embryonic lethality (Duyao et al., 1995; Nasir et al., 1995; 
Zeitlin et al., 1995). Later it was shown that mHTT (YAC46 and YAC72) was able to compensate 
for the absence of wtHTT and rescue the embryonic lethality of mice homozygous for a targeted 
disruption of the endogenous Hdh gene (Leavitt et al., 2001). Moreover HD mutations seem not to 
abrogate the developmental functions of huntingtin, as HD patients appear to develop normally and 
the symptoms start to manifest at the later stage of life (Gil and Rego, 2008). 
Huntingtin is thought to have pro-survival and anti-apoptotic role in the cell. HTT protects 
immortalized striatal-derived cells from apoptotic stimuli by acting down-stream of mitochondrial 
cytochrome C release and preventing the formation of the apoptosome complex and caspase 9 and 3 
activation (Rigamonti et al., 2000; Rigamonti et al., 2001). 
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2.1.1.1 Structure 
Huntingtin does not show structural homology with any other know protein (The Huntington's 
Disease Collaborative Research Group, 1993). HTT is composed of 3114 amino acids depending on 
the amount of polyQ repeats. (Figure 1.) Characterization of full-length HTT by biophysical 
methods suggests that the protein is an elongated superhelical solenoid with a diameter of ∼200 Å 
(1 Å=0.1 nm) (Li et al., 2006). Downstream of the polyQ residues is a polymorphic polyproline 
(polyP) stretch. The polyP and Proline rich domains of mHTT are implicated in a number of 
aberrant protein interactions (Southwell et al., 2008).  
Multiple HEAT domains are the structural domains in HTT (Cattaneo et al., 2001). A HEAT (Htt, 
Elongation factor 3, the PR65/A subunit of protein phosphatase 2A, and the lipid kinase TOR) 
repeat is a ∼50 amino acid long motif consisting of two anti-parallel α-helices forming a helical 
hairpin, which assembles into a superhelix with a continuous hydrophobic core (Southwell et al., 
2008; Southwell et al., 2008). HEAT repeat proteins generally mediate important protein-protein 
interactions involved in cytoplasmic and nuclear transport, microtubule dynamics, and chromosome 
segregation (Li et al., 2006). It has been predicted that HTT contains 28–36 HEAT repeats that span 
the entire protein (Takano and Gusella, 2002). 
The first 17 amino acids of HTT are part of a membrane-targeting domain. This N-terminal stretch 
of huntingtin has been recognized to play an important role together with the first three HEAT 
repeats in targeting huntingtin to various intracellular membrane-bound organelles, including the 
plasma membrane, mitochondria, endosomes, autophagic vesicles, the Golgi apparatus and the ER 
(Atwal and Truant, 2008; Kegel et al., 2005; Rockabrand et al., 2007). 
 
 
Figure 1. Diagram representing huntingtin protein. Amino acid numbering is for the human sequence 
(accession number NP 002102). A stretch of glutamine residues near the N terminus is expanded (polyQ) in 
individuals affected with Huntington's disease. Unaffected individuals typically have fewer than 38 CAG 
repeats. Downstream of polyQ repeats are polyP stretch and ten conserved HEAT repeats. HTT is cleaved at 
various sites by different proteases. PolyP, polyproline; polyQ, polyglutamine; wt, wild-type 
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2.1.1.2 Proteolytic cleavage of HTT 
Earlier studies have shown that inclusions in brains of HD patients and in HD mouse model are 
primarily composed of short truncated derivatives of mHTT. This raised a possibility that 
proteolytic cleavage of HTT plays an important role in HD pathogenesis (DiFiglia et al., 1997; 
Wheeler et al., 2000). Nowadays it is known that HTT protein is cleaved by several different 
proteases; it has caspase, Ca2+ -dependent cysteine protease calpain and aspartyl protease cleavage 
sites as well as less well-defined cleavage fragments. Proteolysis has been shown to increase in the 
presence of longer polyQ tract (Gafni and Ellerby, 2002; Sun et al., 2002). 
Caspase cleavage of HTT and its nuclear accumulation represent early neuropathological changes in 
HD patients. Caspase 3 cleaves HTT at residues 513 and 552 and produces N-terminal fragments of 
HTT including the polyglutamine tract.  The cleavage site at residue 552 is also susceptible to 
caspase 2 (Hermel et al., 2004; Wellington et al., 1998). It has been found that caspases 2, 6, and 7 
recruit HTT in an apoptosome-like complex. Caspases 2 and 7 bound full-length HTT while caspase 
6 bound the N-terminal caspase cleavage product (Hermel et al., 2004). Caspase 6 cleavage site 
resides at site 586. Caspase 6 is reported to have a critical role in early pathogenesis of HD and by 
inhibiting cleavage of caspase 6 substrates, it is possible to influence caspase activation patterns in 
vivo. Mutant HTT fragments are required to initiate a toxic amplification cycle that contributes to 
neuronal dysfunction in HD (Graham et al., 2010). 
Calpains can also cleave huntingtin. Calpain cleavage site at residue 536 leads to the formation of a 
72 kDa N-terminal fragment of huntingtin as an intermediate product. This fragment may be 
cleaved further to generate a 47 kDa product, which is small enough in size to shuttle in and out of 
the nucleus (Gafni and Ellerby, 2002). 
HTT has also been reported to be a substrate for aspartic proteases. Lunkes and colleagues showed 
that clearance of HTT is ensured by a multistep proteolysis involving aspartic proteases and the 
proteasome, which generate N-terminal mHTT fragments with high aggregation potential. This 
proteolysis generates smaller fragments of HTT than caspases and calpains and may be a crucial 
factor for the formation of intranuclear inclusions (Lunkes et al., 2002). 
2.1.1.3 Transcriptional regulation and interacting proteins 
One of the pathogenic processes that have been suggested as the basis for neurodegeneration in HD 
involves interaction of huntingtin with other proteins to produce a change of function and alterations 
of gene transcription.  Mutant HTT can interact with different nuclear proteins and transcription 
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factors by recruiting them into the aggregates and thus inhibiting their transcriptional activity (Gil 
and Rego, 2008). Several transcription factors have been shown to interact with mHTT. These 
include the TBP-associated factor (TAF), specific protein-1 (sp1), CREB [cycline-adenosine 
monophosphate (cAMP) response element (CRE) binding protein]-binding protein and the pro-
apoptotic transcription factor p53 (Dunah et al., 2002; Li et al., 2002; Schaffar et al., 2004; Steffan 
et al., 2000).  
More recently, expression of HTT has been shown to down-regulate transcription of peroxisome 
proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α), a key regulator of 
mitochondrial biogenesis and respiration. (McGill and Beal, 2006) Decreased expression of PGC-1α 
has been considered because mHTT interferes with CREB/TAF4-mediated expression of PGC-1α 
(Cui et al., 2006; Jin and Johnson, 2010). Also the transcription of brain-derived neurotrophic factor 
(BDNF) was reduced in patients with HD (Zuccato and Cattaneo, 2009).  
Different studies have shown that wtHTT interacts with numerous proteins. A study by Kaltenbach 
and colleagues identified 243 high-confidence huntingtin-associated proteins. Relevant examples 
include huntingtin- associated protein 1 (HAP1), a novel protein with at least two isoforms (HAP1-
A and HAP1-B), which is expressed in several tissues including the brain and which interacts with 
the p150 subunit of dynactin, thus being involved in intracellular transport; huntingtin-interacting 
protein 1 (HIP1), a protein that binds to α–adaptin and clathrin, and is thus implicated in 
cytoskeleton assembly and in endocytosis; and huntingtin-interacting protein 2 (HIP2), a ubiquitin-
conjugating enzyme that catalyzes the covalent attachment of ubiquitin units to intracellular proteins, 
tagging them for degradation by the proteasome (Kaltenbach et al., 2007). The presence of an 
expanded polyQ tail can disrupt and/or modify the interactions between HTT and the interacting 
proteins and affect the normal functions of these proteins.  
2.1.1.4 Post-translational modifications 
Post-translational modifications affect protein-protein interactions of HTT and influence its 
subcellular localization. The activity of both wild type and mHTT can be post-translationally 
modified by phosphorylation, ubiquitination, acetylation, palmitoylation and sumoylation (Gil and 
Rego, 2008). 
HTT has several phosphorylation sites and most of these modifications seem to be non-toxic. 
Phosphorylation at serines 13 and 16 has been shown to prevent mHTT induced disease 
pathogenesis in HD mouse models. Phosphorylation of HTT by Akt/protein kinase B at serine 421 
reduces toxic effects of mHTT in vitro (Gu et al., 2009; Humbert et al., 2002; Rangone et al., 2004). 
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Serine 434 phosphorylation by the cyclin-dependent kinase 5 reduces caspase-mediated HTT 
cleavage and attenuates aggregate formation and toxicity in vitro (Luo et al., 2005). 
Covalent attachment of SUMO-1 (small ubiquitin-like modifier) to lysine residues is called 
SUMOylation whereas covalent attachment of a single ubiquitin protein or chains of ubiquitin to 
lysine residues is called ubiquitination. (Ehrnhoefer et al., 2011) In neurons, SUMOylation is 
involved in the transcriptional regulation of neuronal development and function, mitochondrial 
dynamics, the modulation of kinase pathways, synaptic function, and axonal trafficking (Wilkinson 
et al., 2010). Subramaniam et al. showed that Rhes (Ras homolog enriched in striatum) induces 
SUMOylation of mHTT, which leads to cytotoxicity and mHTT disaggregation (Subramaniam et al., 
2009). Ubiquitination plays a role at the synapse in the targeted protein degradation during 
synaptogenesis, synapse elimination and synaptic plasticity (Haas and Broadie, 2008). The ubiquitin 
proteasome system will be discussed later in more detail.  
Acetylation may also control the pathogenicity of HTT.  One study showed that acetylation acts as a 
mechanism for removing accumulated HTT protein in HD (Jeong et al., 2009). Jeong et al. showed 
that acetylated mHTT was trafficked to autophagosomes for degradation which reversed its toxic 
effects.  
Palmitoylation (attachment of a palmitoyl group to proteins) plays an important role in neuronal 
development and synaptic plasticity and can anchor proteins to the plasma membrane and other 
membranes in the cell (Fukata and Fukata, 2010). HTT is palmitoylated at cysteine 214 by the 
palmitoyl transferases HIP14 and HIP14L and a mutation rendering the protein palmitoylation 
resistant leads to increased inclusion body formation and nuclear localization as well as enhanced 
toxicity (Yanai et al., 2006).  
 
2.1.2 Mutant huntingtin 
In HD patients, wt and mHTT have a similar distribution and expression in the body. Although the 
mutant protein is ubiquitously expressed throughout the organism, cell degeneration occurs mainly 
in the brain (Ross and Tabrizi, 2011; Walker, 2007). HD pathogenesis is thought to result from a 
combination of gain-of-function of the mHTT together with the loss-of-function of wtHTT 
physiological function (Cattaneo et al., 2005; Tobin and Signer, 2000). Mutant HTT, in either its 
soluble or insoluble aggregate form, has been shown to disrupt several intracellular pathways, which 
ultimately lead to cell loss in HD. This is discussed in the following sections. 
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2.1.2.1 Aggregation 
The accumulation of nuclear and cytoplasmic protein aggregates or inclusion bodies containing 
mHTT N-terminal polyQ fragments is a pathological hallmark of HD. The protein aggregates have 
been reported in the brains of human patients, in transgenic mouse models and in transfected cell 
models of HD (Nucifora et al., 2001). The mechanisms by which polyglutamine aggregation leads 
to selective neuronal dysfunction and neurodegeneration in HD has not yet been elucidated, but 
several key processes have been identified.  
Aggregates have been considered as the cause of neuronal death based on the facts that there is a 
direct correlation between the frequency of inclusions and severity of the disease (Becher et al., 
1998; Sieradzan et al., 1999). Prolonged mHTT production and formation of aggregates are 
believed to eventually overcome the ability of cells to degrade them via either autophagy or 
proteasomes, leading to an increased load of unmanageable aggregates (Walker, 2007). Mutant HTT 
is more likely to be cleaved by proteases than wtHTT and its truncation facilitates aggregation.  It 
has been shown that aggregates of truncated HTT are toxic and likely to translocate to the nucleus 
(Peters et al., 1999; Wellington et al., 2000). 
The mechanism of HTT aggregation is complex. The normal tertiary protein conformation is 
destabilized by the presence of the expanded polyQ tract, which results in the formation of a toxic 
conformation, which includes a compact β-conformation with short β strands interspersed with β 
turns so that the strands are held together in antiparallel conformation by hydrogen bonds. Initial 
step in the aggregation seems to be accelerated by hydrophobic interactions within an amphipathic 
α-helical structure of 17 amino acids at the N-terminus (Tam et al., 2009; Thakur et al., 2009). 
Mutant HTT can have many different conformations (Kim et al., 2009; Legleiter et al., 2009; 
Legleiter et al., 2010).  
Soluble, intermediate, mHTT species are thought to be more toxic to neurons than the large visible 
intracellular aggregates (Ross and Tabrizi, 2011). Although mHTT aggregates are a pathological 
feature of HD, there has been a great controversy about the nature of the toxic species of mHTT in 
the pathogenesis of the disease. Aggregates have been considered as the cause of neuronal death 
based on the facts that there is a direct correlation between the frequency of inclusions and severity 
of the disease (Becher et al., 1998; Sieradzan et al., 1999). Also the formation of aggregates is 
shown to increase apoptosis in the cell models of HD (Wellington et al., 1998). However there are 
some studies suggesting that aggregates might be a cellular protective process to sequester soluble 
forms of toxic mHTT species. One study showed that formation of the inclusion bodies predicted 
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improved cell survival and leaded to decreased levels of mHTT elsewhere in neurons, thus 
suggesting that formation of aggregates could function as a coping response to toxic mHTT 
(Arrasate et al., 2004). Consistent with this view, in a YAC transgenic mouse model of HD, 
neuronal death was observed in the absence of inclusions (Leavitt et al., 2006). 
 
2.1.3 Neuropathology 
HD neuropathology is characterized by the selective loss of predominantly medium-sized spiny 
neurons (MSNs) in the striatum and to a lesser extent the pyramidal neurons in the deep layers of 
the cortex (Ross and Tabrizi, 2011). In striatum, up to 95% of GABAergic medium spiny projection 
neurons are lost, which projects to the globus pallidus and the substantia nigra (Vonsattel, 2008). 
The most commonly used neuropathological classification of HD was done in 1985 by Vonsattel 
and colleagues. They used postmortem brain specimens from HD patients and made a grading 
system based on the severity of neurodegeneration. This system has five grades (0-4) designated in 
ascending order of severity. Grade 0 has no discernible neuropathological abnormalities. The 
earliest changes were seen in the medial paraventricular portions of the caudate nucleus (CN), in the 
tail of the CN, and in the dorsal part of the putamen. Counts of neurons in the CN reveal that 50% 
are lost in grade 1 and that 95% are lost in grade 4; astrocytes are greatly increased in grades 2-4 
(Vonsattel et al., 1985). In stages 1 and 2 nonstriatal structures show generally a slight atrophy, 
whereas in grades 3 and 4 the cerebral cortex, globus pallidus, thalamus, subthalamic nucleus, 
substantia nigra, white matter and cerebellum can be affected (Vonsattel and DiFiglia, 1998). Also 
hypothalamus can be atrophied in HD patients (Kassubek et al., 2004). The overall brain weight can 
decrease ultimately by up to 40% in HD patients. The loss of brain weight is known to precede the 
loss of body weight and the onset of neurological symptoms (Vonsattel and DiFiglia, 1998). 
Advances in neuroimaging have given a better understanding of HD pathology. Structural 
neuroimaging has elucidated the correlation between morphological brain changes in striatum and 
cortex, and the development of cognitive deficits in attention, working memory and executive 
functions in HD (Montoya et al., 2006). 
Mutant HTT is ubiquitously expressed in the brain and it is still unknown why HD neuropathology 
is largely restricted to the striatum. Loss of BDNF (brain-derived neurotrophic factor) support from 
cortical-striatal projections and excitotoxicity has been proposed to account for striatal selectivity 
(Cowan and Raymond, 2006; Wang et al., 2008). Also interaction between HTT and the Rhes (ras 
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homolog enriched in striatum) protein could account for striatal selectivity. The small guanine 
nucleotide–binding protein Rhes, localized very selectively to the striatum, induces SUMOylation 
of mHTT, which leads to cytotoxicity (Subramaniam et al., 2009). SUMOylation of mHTT was 
shown to increase its soluble form and to elicit cytotoxicity and neurotoxicity in a Drosophila model 
of HD (Steffan et al., 2004). Deletion of Rhes reduces striatal degeneration and motor dysfunction 
in a toxin model of HD and Rhes deleted mice have delayed onset of symptomatology (Baiamonte 
et al., 2013; Mealer et al., 2013). A recent study showed that Rhes has a role in autophagy; deletion 
of endogenous Rhes decreased autophagy, while Rhes overexpression activated autophagy. These 
effects are independent of mTOR and opposite in the direction predicted by the known activation of 
mTOR by Rhes. Rhes robustly binds the autophagy regulator Beclin-1, decreasing its inhibitory 
interaction with Bcl-2 independent of JNK-1 signaling. The regulation of autophagy by Rhes may 
account for the delayed onset of HD neuropathology (Mealer et al., 2013). 
 
2.1.4 Model systems of Huntington’s disease 
Our knowledge about Huntington’s disease biology mainly arises from studies of model systems, 
ranging from cellular models to invertebrates to mammals. All of these models have limitations but 
also strengths. Although not perfect, these models are essential for modeling the human disease, 
which is not feasible with postmortem human HD brains (Ross and Tabrizi, 2011). Different model 
systems are necessary in understanding the pathogenesis of HD and developing early diagnostic and 
therapeutic applications.  
2.1.4.1 Cell models 
Cell lines are useful for biochemical studies and can be used for transient, stable or inducible 
expression strategies. Disadvantage with different cell lines is that they might not recapitulate the 
cell biology of neurons, yet primary neurons can be used to model many features of neurons in vivo 
(Ross and Tabrizi, 2011). 
The HD Consortium reported the generation and characterization of 14 induced pluripotent stem 
cell (iPSC) lines from HD patients and controls. Through an international consortium effort 
involving eight research groups, it was shown that HD iPSC lines had clear, reproducible CAG 
repeat- expansion-associated phenotypes upon differentiation. The utility of this model system 
includes elucidation of HD cellular pathogenesis, development of HD specific biomarkers, and 
ultimately screening for small molecule or other therapeutic interventions (HD iPSC Consortium, 
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2012).  One recent study showed that iPSCs derived from HD patient fibroblasts can be corrected by 
the replacement of the expanded CAG repeat with a normal repeat using homologous recombination. 
The corrected cells retained pluripotent characteristics and were able to be differentiated into striatal 
neurons. Correction of the HD-iPSCs normalized pathogenic HD signaling pathways and reversed 
disease phenotypes such as susceptibility to cell death and altered mitochondrial bioenergetics in 
neural stem cells. (An et al., 2012) 
2.1.4.2 Animal models 
Animal models of Huntington’s disease are useful in the study of the early disease stages for which 
patient material is rarely available. First animal models for HD were developed already in the 1970s 
on the basis of selective vulnerability of striatal neurons to exitotoxic aminoacids (Coyle and 
Schwarcz, 1976). Nowadays there are several commercially available genetically engineered 
animals carrying part or the full length of the mutated gene causing Huntington disease (HD). 
Transgenic animal models for HD were first created in mice and subsequently in invertebrates 
(Bates et al., 1997; Mangiarini et al., 1996; Marsh et al., 2003).  
Invertebrate models of HD include Drosophila and Caenorhabditis elegans. These models are 
useful for rapid tests of therapeutic interventions. However the extent to which they resemble 
human HD biology is uncertain (Marsh et al., 2003; Ross and Tabrizi, 2011). 
Intranuclear inclusions of mHTT were first discovered in the R6/2 mouse model, which expresses 
the first exon of the human HD gene carrying 141–157 CAG repeat expansions. Mouse models 
expressing N-terminal fragments of HTT (for example the R6/2 model and the N171-82Q model) 
seem to have the most robust and rapidly progressive phenotypes, including incoordination, 
cognitive and other behavioral abnormalities and weight loss progressing to early death. Thus these 
models have frequently been used in therapeutic trials (Heng et al., 2008; Ross and Tabrizi, 2011). 
Mice expressing flHTT (BAC and YAC mouse models) generally present more subtle phenotypes 
than mice expressing N-terminal fragments, but have more selective neurodegeneration. The BAC, 
YAC and knock-in models are useful for studies where the entire HTT protein is needed, such as 
studies of cleavage of flHTT and studies of stages before behavioral and pathological phenotypes 
(Ross and Tabrizi, 2011). In addition to mouse models, a transgenic rat model carrying N-terminal 
HTT (51Q) is available (von Horsten et al., 2003). This model displays adult-onset neurological 
phenotypes with reduced anxiety, cognitive impairments, and slowly progressive motor dysfunction 
as well as neuronal nuclear inclusions in the brain and aggregates in the striatum. HD transgenic rats 
are well suited for complex behavioral studies and the evaluation of in vivo progression markers 
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using high-resolution PET and MRI (von Horsten et al., 2003). In conclusion, a variety of different 
rodent models of HD are available and different features of these models confer different 
advantages and disadvantages, depending on specific experimental aims (Heng et al., 2008). 
HD non-human primate model was established in a rhesus macaque using a lentiviral vector to 
deliver green fluorescent protein-tagged HTT exon 1 with 84 CAG repeats into unfertilized monkey 
egg cells. These transgenic monkeys have hallmark features of HD, including nuclear inclusions and 
aggregates, in the brain, and showed important clinical features of HD including dystonia and 
chorea. Thus the transgenic HD monkeys may provide the opportunity for a wide range of 
behavioral and cognitive assessments that are identical to or close to the assessments used for 
human patients (Yang et al., 2008). 
The sheep, Ovis aries L., is another mammalian model for studying HD. This ovine model was 
generated through a ligation of a FL human HTT cDNA containing 73 polyglutamine repeats under 
the control of the human promoter into the genome using pronuclear microinjection. This novel 
transgenic animal could represent a practical model for drug/clinical trials and surgical interventions 
especially aimed at delaying or preventing HD initiation (Jacobsen et al., 2010). 
Although useful in research, transgenic animal models are not always applicable to human HD 
because of species differences and variations in HTT gene length, promoters, and mechanisms of 
expression. Animal models are usable in drug screenings as an animal with a lifespan of days or 
months elucidates a fast screening of different compounds. (Bates et al., 1997; Walker, 2007). 
 
2.1.5 Treatment and therapy 
Although the genetic basis of the disease has been identified, our understanding of the HD 
pathogenesis is still incomplete, and there is no cure or treatment to delay the onset or slow the 
progression of the disease. Reducing the amount of mHTT is believed to be an effective strategy 
against HD. However there are only few validated targets that regulate mHTT protein levels. 
Many clinical trials in HD have been done in the past ten years, but no drugs have been proven to be 
efficacious. Clinical trials are really challenging, because of the slow progress of HD and its clinical 
heterogeneity (Mason and Barker, 2009; Ross and Tabrizi, 2011). Most studies have been open-
label, using a small number of patients and tended to concentrate on the motor features of the 
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disease, primarily the chorea (Mason and Barker, 2009; Ross and Tabrizi, 2011). The best 
therapeutic option for HD treatment is to start in the asymptomatic phase of the disorder.  
Currently there are only symptomatic drugs available for treating the illness. (Table 2.) Dopamine, 
glutamate, and γ-aminobutyric acid are thought to be the most affected neurotransmitters in HD and 
are currently the focus of pharmacotherapy. Pharmacological interventions typically address the 
hyperkinetic movement disorders that may be associated with HD, such as chorea and dystonia 
(Frank, 2013). To date, tetrabenazine (TBZ), a dopamine depleting agent, is the only 
pharmacotherapy shown to have a clinically meaningful, statistically significant effect on chorea 
(Pidgeon and Rickards, 2013). 
2.1.5.1 Potential new treatments  
There are a number of ongoing or recently completed clinical studies in HD (Frank, 2013). However, 
recently completed studies have shown no or little benefit for cognitive or motor symptoms 
(Huntington Study Group TREND-HD Investigators, 2008; Kieburtz et al., 2010). Hence there is a 
need for treatment options that could change the course of the disease.  Some ongoing studies are 
evaluating supplements that may affect metabolism or mitochondrial function implicated in HD to 
potentially change the course of disease. The largest include the 5-year study of coenzyme Q10 
(2CARE) and the 3-year study of creatine (CREST-E). The green tea extract polyphenon (2)-
epigallocatechin-3-gallate is under study for its effect on cognition in patients with HD (Frank, 2013; 
Yang et al., 2009). 
Another potential intervention under study is the use of RNA interference to reduce the expression 
of mHTT. RNA interference may be delivered using a viral vector or through direct infusion into 
the basal ganglia, and both systems are under study, although not yet in humans (Drouet et al., 2009; 
Frank, 2013). 
Cell-replacement therapy for HD has given positive outcomes in clinical trials. In this therapy lost 
striatal neurons are replaced by fetal medium spiny neuron transplants or diverse stem cell 
transplants. These experiments were done using human fetal transplants grafted into animal hosts. 
There are still many issues to be addressed concerning reproducibility, stability, safety and quality 
control, as well as the more complex issues involving directed differentiation into the precise 
neuronal phenotypes required to replace the function of lost striatal neurons connected within 
complex neuronal circuits of the host basal ganglia (Kelly et al., 2009). 
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Studies with cellular and animal models of HD have shown that rapamycin can protect against 
neurodegeneration induced by aggregated mHTT, by enhancing their clearance via autophagy. 
Rapamycin is a US Food and Drug Administration (FDA)-approved antibiotic and 
immunosuppressant drug. It induces autophagy by inhibiting the activity of mammalian target of 
rapamycin (mTOR) and attenuates mHTT toxicity in various HD models (Bove et al., 2011). 
Several mTOR-independent inducers of autophagy had similar beneficial effects than rapamycin, 
including lithium, trehalose and a series of autophagy-inducing compounds identified from either a 
small-molecule yeast screen or a library of FDA-approved drugs, (Bove et al., 2011; Sarkar et al., 
2005; Sarkar et al., 2007; Sarkar and Rubinsztein, 2008). Effects of rapamycin in mHTT clearance 
are mostly observed at early stages of protein aggregation in the presence of micro aggregates and 
soluble HTT. This indicates that treatment with rapamycin should be aimed at early stages of the 
disease, when large, highly stable aggregates have not yet been formed. Pre-symptomatic treatment 
with autophagy inducers could potentially be feasible in HD, and eventually delay, or even prevent, 
disease onset (Bove et al., 2011). Autophagy in the context of HD will be discussed in more detailed 
in later chapters. 
 
2.2 Endoplasmic reticulum stress 
Secreted and membrane proteins are synthetized in the ribosomes bound to ER. After that they fold 
and mature in the ER before their delivery to other compartments in the endomembrane system, 
display on the cell surface or release to the extracellular space. The rates of protein synthesis, 
folding and trafficking are controlled to ensure that only properly folded proteins exit the ER (Tabas 
and Ron, 2011; Wang and Kaufman, 2012). Disturbance in the function of this organelle leads to the 
accumulation of unfolded or misfolded proteins inside the ER, a cellular condition referred as ER 
stress (Hetz et al., 2013). Factors that can contribute to the development of ER stress include; 
increased protein synthesis or protein misfolding rates that exceed the capacity of protein 
chaperones, alterations in calcium stores in the ER lumen, oxidative stress and disturbances to the 
redox balance in the ER lumen (Tabas and Ron, 2011). Misfolded proteins are either retained within 
the ER or degraded by the proteasome-dependent ER-associated protein degradation (ERAD) 
pathway or by autophagy (Wang and Kaufman, 2012). ER stress can induce autophagy for removal 
of unfolded proteins independently of the ubiquitin/proteasome system, which may be particularly 
important when severe protein misfolding results in insoluble protein aggregates that cannot be 
eliminated by the proteasome (Kim et al., 2008).  
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ER stress is sensed by three upstream signaling proteins that trigger different cascades. The activity 
of these three pathways collectively constitutes an ER-specific unfolded protein response (UPR). 
Activation of the UPR strives to restore protein-folding homeostasis, but when the cell damage is 
sufficiently severe, UPR signaling results in cell death by apoptosis (Hetz et al., 2013; Tabas and 
Ron, 2011). Dysfunction of ER quality control system causes conformational diseases (caused by 
adoption of non-native protein conformations that lead to aggregation) such as diabetes mellitus, 
ischemic diseases and neurodegenerative disorders, like Huntington’s disease. Thus, the 
understanding of the molecular mechanisms of the ER stress may provide insight on the potential 
therapeutic target for diseases (Hetz et al., 2013). 
 
Figure 2. The Unfolded protein response. Three sensors control UPR-dependent responses; IRE1α, PERK and 
ATF6. Each of these ER transmembrane proteins uses a different mechanism of signal transduction: ATF6 
signals via regulated proteolysis, PERK via translational control and IRE1 via nonconventional mRNA splicing. 
A) IRE1α RNase activity processes the mRNA encoding XBP1. This leads to the expression of an active 
transcription factor (XBP1) that upregulates a subset of organelle biogenesis. IRE1α also degrades select 
mRNAs through a process called regulated IRE1-dependent decay pathway. In addition, IRE1α activates the 
JNK-ASK1pathway through the binding to adaptor proteins. B) Activation of PERK attenuates general protein 
synthesis through phosphorylation of eIF2α, which allows the selective translation of the ATF4 mRNA 
encoding a transcription factor that induces the expression of genes involved in antioxidant responses, amino 
acid metabolism, autophagy and apoptosis. ATF4 controls the expression of the pro-apoptotic components 
GADD34 and CHOP. GADD34 dephosphorylates eIF2α. C) ER stress induces translocation of ATF6 to Golgi 
apparatus where it is processed by a site 1 protease (S1P) and site 2 protease (S2P) releasing its cytosolic 
domain (ATF6f) which controls the upregulation of select UPR target genes. Modified from (Hetz et al., 2013; 
Walter and Ron, 2011). 
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2.2.1 Unfolded protein response 
In mammals there are three UPR sensors: inositol-requiring enzyme 1 (IRE1), protein kinase RNA-
like ER kinase (PERK) and activating transcription factor 6 (ATF6) (Figure 2.) (Hetz et al., 2013). 
Each UPR sensor binds to the ER luminal chaperone Bip. When misfolded proteins accumulate in 
the ER, they bind to and sequester Bip (immunoglobulin binding protein, also called Grp78) and 
activate the ER stress sensors (Bertolotti et al., 2000). However, additional mechanisms that initiate 
and modulate the activity of different UPR sensors have been reported (Gardner and Walter, 2011; 
Promlek et al., 2011). While IRE1, PERK and ATF6 activation proceeds independently in ER-
stressed cells, the three arms of the UPR communicate with each other extensively. For example 
CHOP is a transcriptional target not only for ATF4 (PERK pathway) but also XBP-1 (IRE1 
pathway) and ATF6 (Tabas and Ron, 2011). 
2.2.1.1 IRE1  
The IRE1 branch is the most conserved pathway of the UPR and present from lower eukaryotes to 
human. In mammals IRE1 has two homologues, IRE1α and IRE1β. IRE1α is expressed in all cells 
and tissues, whereas IRE1β is expressed only in the gastrointestinal and respiratory tracts. The 
function of IRE1β is still unknown and UPR signaling is mainly mediated through IRE1α (Wang 
and Kaufman, 2012). Under ER stress, IRE1 is activated which involves its trans-
autophosphorylation, oligomerization and dimerization. These conformational changes lead to 
activation of its cytoplasmic kinase and ribonuclease domains. Activation of IRE1 is probably 
initiated both by ER stress induced changes in protein interactions, such as dissociation of Bip and 
by direct binding to unfolded proteins (Ron and Walter, 2007). Active cytoplasmic nuclease domain 
of IRE1 cleaves the mRNA encoding a UPR-specific transcription factor, called XBP1 (X-box 
binding protein 1). The resulting spliced mRNA is translated to the active form of the transcription 
factor XBP1, which targets a wide variety of genes encoding proteins involved in ER membrane 
biogenesis, protein folding, ERAD, and protein secretion from the cell (Wang and Kaufman, 2012). 
Under certain conditions, the IRE1 nuclease can degrade and block the translation of several mRNA 
species. The possible physiologic and pathologic functions of this action are still poorly understood 
(Hollien and Weissman, 2006; Hollien et al., 2009). In addition IRE1 can cleave microRNAs, which 
affect the regulation of apoptosis (Upton et al., 2012). 
 
IRE1 promotes not only the UPR but also the apoptotic signaling. IRE1α interacts with TNF (the 
adaptor tumor necrosis factor) receptor-associated factor 2 (TRAF2) to instigate the downstream 
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activation of ASK1 (apoptosis signal-regulating kinase 1) and JNK (JUN N-terminal kinase) (Han et 
al., 2009; Hetz et al., 2013). 
2.2.1.2 PERK  
Activation of PERK involves trans-autophosphorylation and dimerization, similar to IRE1 
activation. Under ER stress active PERK phosphorylates eukaryotic translation initiator factor 2α 
(eIF2α), which leads to the inhibition of protein synthesis. This has a pro-survival role in the cell, as 
it reduces the number of proteins entering the ER (Harding et al., 2000). Phosphorylation of eIF2α 
can also change the efficiency of AUG initiation codon utilization and allow the translation of 
mRNAs containing short open reading frames in their 5’-untranslated regions, such as activating 
transcription factor 4 (ATF4) (Lange et al., 2008). ATF induces the expression of genes involved in 
ER function but also in apoptosis, including the transcription factor C/EBP-homologous protein 
(CHOP) and growth arrest and DNA damage-inducible protein 34 (GADD34) (Hetz et al., 2013). A 
recent study showed that transcriptional induction through ATF4 and CHOP increased protein 
synthesis leading to oxidative stress and cell death. They showed that increased protein synthesis 
generates ROS, which are a necessary signal to induce apoptosis in response to ER stress. Their 
findings suggested that limiting protein synthesis would be therapeutic for diseases caused by 
protein misfolding in the ER (Han et al., 2013). Phosphorylation of eIF2α is a key mechanism to 
slow protein translation and prevent oxidative stress and apoptosis under prolonged ER stress. 
GADD34 promotes the dephosphorylation of eIF2α and thus restores protein translation and 
represents a pro-apoptotic mechanism (Han et al., 2013).  
2.2.1.3 ATF6 
ATF6 is an ER-associated type 2 transmembrane basic leucine zipper transcription factor. Under ER 
stress ATF6 dissociates from Bip and translocates to the Golgi apparatus for cleavage by serine 
site1 protease (S1P) and site 2 protease (S2P), which releases the transcription-activating form of 
ATF6, ATF6f (Schindler and Schekman, 2009). Among other target genes, ATF6f regulates the 
expression of genes of the ERAD pathway and genes encoding ER-resident proteins involved in 
protein folding (Lee et al., 2002). 
 
2.2.2 Endoplasmic reticulum stress in HD 
The role of ER stress in the nervous system is not fully understood but activation of the UPR is 
observed in several neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson’s 
disease, Alzheimer’s disease, multiple sclerosis, and Huntington’s disease (Lindholm et al., 2006). 
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Several studies suggest a possible involvement of ER stress in the pathogenesis of HD, however the 
actual contribution of the UPR to the disease process in vivo is still poorly defined. Carnemolla and 
colleagues showed in a mouse model of HD that ER stress is an early event, which precedes the 
formation of intranuclear and/or cytoplasmic mHTT aggregates. They also confirmed ER stress in 
the postmortem brains of HD patients, by observing the transcriptional regulation of UPR genes, 
like CHOP and Bip (Carnemolla et al., 2009). Many studies have also shown that ER stress 
contributes to neurodegeneration in cellular models of HD (Kouroku et al., 2002; Urano et al., 2000; 
Vidal et al., 2011). In neuronal PC6.3 cells mHTT expression was shown to induce ER stress with 
elevation of Bip, cleavage of caspase-12 and the activation of different ER signaling pathways 
including the CHOP and the JNK pathways (Reijonen et al., 2008). 
HTT functions as an ER-associated protein. It has a domain within the first 18 amino acids that has 
an amphipathic α-helical structure able to reversibly associate with ER. HTT can translocate to the 
nucleus and back out in response to ER stress (Atwal and Truant, 2008). ER stress response to 
temperature shift or induction of the UPR seems to release HTT from the ER in a striatal-derived 
mouse cell line (Atwal and Truant, 2008). Although HTT interacts with the surface of the ER, it has 
not been described inside the ER lumen. There is evidence of dysfunction in many cellular 
pathways in different HD models, including ERAD/protein quality control mechanisms, ER/Golgi 
trafficking, endocytosis, vesicular trafficking, ER calcium homeostasis and autophagy/lysosomal-
mediated protein degradation. These defects are predicted to impact the protein folding status in the 
ER and to generate ER stress (Vidal et al., 2011). 
Therapeutic strategies to alleviate ER stress may be beneficial for HD patients. In a cellular HD 
model, inhibition of ER stress by the compound salubrinal, a specific inhibitor of eIF2α phosphatase 
enzymes, reduced ER stress and counteracted cell degeneration. Salubrinal also reduced mHTT 
aggregates, suggesting that inhibition of ER stress may directly or indirectly regulate the 
accumulation of protein aggregates in the cell and in the membrane (Reijonen et al., 2008). A recent 
study indicated a protective effect of XBP1 deficiency in neurodegeneration using knockout mice 
and suggested a potential use of gene therapy strategies to manipulate the UPR in the context of HD 
(Zuleta et al., 2012).  
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2.3 Cell Death 
Cell death is classified into two categories according to their morphological structures: apoptosis 
and necrosis. Whereas apoptosis is considered as a controlled, active form of cell death, necrosis is 
an uncontrolled and passive breakdown of cellular contents (Kroemer et al., 2005). However certain 
cell types have been shown to undergo “programmed necrosis” or “necroptosis” which is a 
programmed necrosis that involve specific molecular machinery (Bizik et al., 2004). Necroptosis 
participates in the pathogenesis of diseases, including ischaemic injury, neurodegeneration 
(Vandenabeele et al., 2010). The initiation of “necroptosis” involves many proteins, including 
Tumor necrosis factor (TNF) and caspase inhibitors. Excitotoxicity, oxidative stress and 
mitochondrial dysfunction, all contribute to the execution of necroptosis and are also implicated in 
Huntington's disease (Lin and Beal, 2006; Vandenabeele et al., 2010). Autophagy, discussed later, 
has been morphologically defined as a type of cell death, but its role in executing cell death is 
controversial (Kroemer et al., 2005).  
 
Figure 3. Extrinsic and intrinsic apoptotic pathways. The extrinsic pathway involves extracellular signals 
through cellular death receptors that cause intracellular interactions that lead to cell death. Cell death is also 
caused intrinsically. Any type of stress in the endoplasmic reticulum (ER), such as an accumulation of unfolded 
and unstable proteins or a disruption in the homeostasis of the ER can cause the activation of caspase 12, which 
then cleaves caspase 9 initiating the death cascade. Cytochrome C release is initiated via the intrinsic pathway 
in which intracellular death signals are translocated to the mitochondria stimulating the release of apoptogenic 
factors. Upon release from the mitochondria, cytochrome C interacts with cytosolic protein factors, Apaf1 and 
procaspase 9, and the complex begins the cascade which is completed by the executioner caspases, such as 
caspases 3, 6, and 7 in the cascade result in cell death. Calpain is activated by intracellular Ca2+ overload. Once 
activated, calpain hydrolyses its substrates in the cytosol, nucleus and membrane, resulting in apoptosis. 
Modified from (Pattison et al., 2006).  
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Apoptosis is a genetically regulated form of cell death with distinct biochemical and morphological 
features. Deregulation of apoptosis causes several human disorders including cancer, autoimmune 
and neurodegenerative diseases (Agostini et al., 2011). Apoptosis was first defined by Kerr and 
colleagues in 1972. They stated that the structural changes during apoptosis occur in two discrete 
stages. The first comprises nuclear and cytoplasmic condensation and breaking up of the cell into a 
number of membrane-bound, ultra structurally well-preserved fragments. In the second stage, these 
apoptotic bodies are shed from epithelial-lined surfaces or are taken up by other cells, where they 
undergo a series of changes resembling autolysis within phagosomes, and are rapidly degraded by 
lysosomal enzymes derived from the ingesting cells (Kerr et al., 1972). Other features of apoptosis 
are a reduction in the membrane potential of the mitochondria, intracellular acidification, generation 
of free radicals, and externalization of phosphatidylserine residues on the plasma membrane 
(Agostini et al., 2011). 
 
The major executioners in the apoptotic program are proteases known as caspases (cysteine-
dependent aspartate-specific proteases). Caspases are cysteine proteases that exist as latent 
precursors, which, when activated, initiate the death program by destroying key components of the 
cellular infrastructure and activating factors that mediate damage to the cells. Procaspases are 
composed of p10 and p20 subunits and an N-terminal recruitment domain. Active caspases are 
heterotetramers consisting of two p10 and two p20 subunits derived from two procaspase molecules. 
A critical aspect of caspase-mediated cell death lies in the events regulating the activation of 
initiator caspases. Two major pathways exist by which initiator caspases lead to cell death - one is 
extrinsic, the other intrinsic (stress or mitochondria-mediated) pathway (Figure 3.). The extrinsic 
pathway involves extracellular signals through cellular death receptors that cause intracellular 
interactions that lead to cell death. In HD caspases are also transcriptionally up-regulated (Pattison 
et al., 2006). 
Other proteases called calpains are also involved in the apoptotic signaling process. Calpains are 
calcium-activated cysteine proteases that are involved in neuronal cell death and activated by 
increased intracellular calcium from the ER or mitochondria or an influx of extracellular calcium. 
Calpains are known to cleave many important regulators of apoptosis and to cross-talk with caspase 
cascades (Harwood et al., 2005; Kidd et al., 2000). Activated calpains have been detected in 
striatum of HD knock-in mouse models and postmortem HD human brain (Cowan and Raymond, 
2006; Gafni and Ellerby, 2002; Gafni et al., 2004).2.3.1 Cell death induced by ER stress 
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Cell death is induced under prolonged ER stress, typically by apoptosis. However, ER-stress-
induced cell death can proceed even without caspase activity, and the cell death mechanisms 
triggered as a result of ER stress are diverse, involving both caspase-dependent apoptosis and 
caspase-independent necrosis (Kim et al., 2008). ER stress-induced cell death is a complex and 
highly regulated process carefully controlled by ER localized stress receptors. Based on recent 
studies IRE1α and PERK signals are important in cell death commitment (Logue et al., 2013). 
Prolonged activation of IRE1 and CHOP can trigger apoptosis. At high level of stress IRE1 
contributes to the degradation of membrane-associated mRNAs through a process called regulated 
IRE1 dependent decay (RIDD) which may be a mechanism of apoptosis and other possible link 
between IRE1 and ER stress induced apoptosis is the interaction of IRE1 with different proteins 
involved in apoptosis signaling. For example IRE1 may be involved in the ER stress-induced 
apoptosis by interacting with the B-cell leukaemia/lymphoma 2 (BCl-2) family of proteins, a 
diverse group of proteins that regulate cell death. The pro-apoptotic proteins BCl-2-associated X 
protein (BAX) and BCl-2 antagonist/killer (BAK) are reported to physically interact with and 
activate IRE1α. BAX and BAK are pro-apoptotic and they initiate intrinsic apoptosis through the 
release of cytochrome C and assembly of the apoptosome (Figure 3.). The IRE1α–ASK1–JNK 
signaling pathway is also connected to a cell death mechanism, whereby JNK-mediated 
phosphorylation has been reported to activate the pro-apoptotic BCl-2 family member BIM, while 
inhibiting the antiapoptotic protein BCl-2. IRE1 activation also triggers the recruitment of caspase 
12, which different studies have claimed functionally important in ER-stress-induced apoptosis 
(Kim et al., 2008; Lei and Davis, 2003; Szegezdi et al., 2003; Tabas and Ron, 2011). 
Loss of PERK-mediated eIF2α phosphorylation markedly sensitizes cells to death from ER stress. 
However, not all of the effectors of this arm of the UPR contribute to protection; a notable 
exception is the transcription factor CHOP, which is itself transcriptionally induced by eIF2α 
phosphorylation.  CHOP operates downstream of all ER-stress pathways. The IRE1–ASK1–p38 
MAPK pathway enhances CHOP activity at a post-transcriptional level. Overexpression of the 
CHOP protein is shown to induce apoptosis through a mechanism that could be inhibited by BCl-2 
(McCullough et al., 2001; Wang and Ron, 1996). Another mechanism implicated in CHOP-induced 
apoptosis is oxidative stress. Prolonged ER stress can both hyperoxidize the ER lumen, which may 
result in H2O2 leakage into the cytoplasm, and directly induce cytotoxic reactive oxygen species 
(ROS) in the cytoplasm. Oxidation of the ER lumen is induced by the CHOP transcriptional target 
ER oxidase 1α (ERO1α). The CHOP-ERO1α pathway can induce pro-apoptotic oxidative stress 
(Tabas and Ron, 2011). 
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2.4 Oxidative stress in HD 
It has been speculated that there is energetic impairment in HD because the weight loss of the 
patients despite sustained caloric intake. Further, PET scans revealed marked reductions in glucose 
metabolism in the striatum of HD patients in early stages prior to pronounced striatal atrophy. These 
studies revealed that energy dysfunction precedes the onset of clinical symptoms of the disorder, 
suggesting that an energy failure may play a primary role in the pathogenesis of HD (Browne, 2008; 
Kuwert et al., 1990; Quintanilla and Johnson, 2009). 
Several different studies have demonstrated that alterations in mitochondrial function play a key 
role in the pathogenesis of HD. The net results of these events are compromised energy metabolism 
and increased oxidative damage, which eventually contribute to neuronal dysfunction and death 
(Andersen, 2004). Studies in HD patients and HD post-mortem tissue have shown 
decrease/dysfunction in the activities of different mitochondrial complexes (Gil and Rego, 2008). 
Mutant HTT was also shown to disrupt mitochondrial-dependent Ca2+ handling (Oliveira et al., 
2006). In addition mHTT can affect mitochondrial function by inhibiting the expression of PGC-1α, 
which is related to impaired ATP production and a reduction in intact mitochondria (Weydt et al., 
2006). PGC-1α is a transcriptional co-regulator of mitochondrial biogenesis and antioxidant 
enzymes. The suppression of PGC1-α by mHTT is also cause of mitochondrial-dependent 
generation of reactive oxygen species (ROS).  
 
 
Figure 4.  Effect of increased ROS production in neurodegeneration. mHTT causes damage to 
mitochondria, which then produce harmful ROS, which in turn damage more mitochondria. Modified from 
(Andersen, 2004). 
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2.4.1 Reactive oxygen species and antioxidants 
ROS are highly toxic to cells. ROS include superoxide, hydroxyl and peroxyl free radicals, as well 
as nitrogen intermediates (NO and peroxynitrile). Oxidative stress can lead to a toxic increase in 
ROS production causing damage to cell membranes and aborting normal cellular functions. (Figure 
4.) ROS can inflict oxidative molecular damage to lipids, proteins and nucleic acids. Mitochondria 
are the major source of ROS. Apart from mitochondria, the ER produces ROS during normal cell 
metabolism and protein folding. Because of the high metabolic rate and relatively reduced capacity 
for cellular regeneration, the brain is particularly susceptible to oxidative stress and ROS (Andersen, 
2004; Johri and Beal, 2012). Oxidative alterations to proteins may cause increased protein 
misfolding and impaired degradation, leading to toxic accumulation of insoluble mHTT aggregates 
in the brain and ultimately to neurodegeneration. Increased oxidative damage and an increased 
production of ROS have been reported in cellular an animal models of HD (Perez-Severiano et al., 
2002; Reijonen et al., 2010).  
The burden of ROS production is largely counteracted by an antioxidant defense system including 
the enzymatic scavengers superoxide dismutase (SOD), thioredoxins 1 and 2 (Trx1, Trx2), catalase 
and glutathione peroxidase. SOD speeds the conversion of superoxide to hydrogen peroxide, 
whereas catalase and glutathione peroxidase convert hydrogen peroxide to water and thioredoxins 
catalyze reduction of disulfides. The balance between ROS production and antioxidant defenses 
determines the degree of oxidative stress (Finkel and Holbrook, 2000). Antioxidants have been 
shown to be effective in slowing disease progression in transgenic mouse models of HD, and have 
shown promise in human clinical trials. Strategies to transcriptionally increase the expression of 
antioxidant enzymes by increasing the expression of PGC-1α have also been proposed as a 
therapeutical alternative to slow or halt the progression of HD (Johri and Beal, 2012). 
 
2.4.2 Oxidative stress and cell death 
Apart from being a major contributor to oxidative stress, mitochondria are also central players in the 
process of caspase activation and apoptosis. HTT is known to associate with the outer mitochondrial 
membrane and a truncated mHTT fragment can directly induce the opening of the mitochondrial 
permeability transition pore (MPTP) in isolated mouse liver mitochondria, which is accompanied by 
a significant release of cytochrome C (Choo et al., 2004). Cytochrome C leads to caspase activation 
which in turn can cleave mHTT and promote its translocation into the nucleus, where it abnormally 
interacts with several transcription factors. Transcription factor p53 regulates the expression of 
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various mitochondrial proteins such as Bax and interacts with mHTT in HD lymphoblasts and in 
neuronal cells expressing mHTT (Bae et al., 2005; Steffan et al., 2000). In neuronal cultures, mHTT 
induces an upregulation of the nuclear levels of p53 and enhance its activity. Interestingly, p53 
levels are also increased in HD transgenic mice and in HD patients. Thus, it is likely that mHTT-
induced increase in p53 activity induces further mitochondrial abnormalities that contribute to HD 
(Bae et al., 2005). 
Proteins that prevent or promote apoptosis can affect intracellular Ca2+ dynamics and homeostasis 
through binding and modulation of the intracellular Ca2+ release and Ca2+ uptake mechanisms. 
Oxidative stress becomes an additional factor that affects ER and mitochondrial function and thus 
their role in Ca2+ signaling (Decuypere et al., 2011). The expression of Bcl-2, the major 
antiapoptotic member of the Bcl-2 family, is under complex control of several factors, including 
ROS. Bcl-2 prevents apoptosis caused by a variety of cellular stresses such as oxidative stress. It 
localizes at mitochondrial outer membranes, as well as to the ER. One of the primary actions of Bcl-
2 is to block homodimerization of proapoptotic Bax at mitochondria. Bcl-2 also regulates the Ca2+ 
mobilization at the ER (Meunier and Hayashi, 2010). ROS is known to decrease the expression of 
bcl-2 mRNA by promoting CRE-binding protein (CRBP) or NF-κB to CRE and κB sequences on 
the bcl-2 promoter (Pugazhenthi et al., 2003). Downregulation of NF-κB signaling was linked to 
decreased antioxidant levels, increased oxidative stress, and enhanced cell death in neuronal cells 
expressing N-terminal mutants and the disease-inducing variant of full-length HTT (Reijonen et al., 
2010). 
Several studies have reported impairment of the intracellular Ca2+ modulation in HD. Mutant HTT 
has been associated with the altered expression of some genes involved in Ca2+ homeostasis both in 
human patients and in HD animal models. Direct binding of mHTT to proteins involved in Ca2+ 
handling has also been reported. However, it is still unclear whether the transcriptional effects in 
HD neurons are a cell adaptation response to the variations of intracellular Ca2+, which could be due 
to the direct interaction of mHTT with Ca2+ binding/ Ca2+ transport proteins, or whether the changes 
of Ca2+ levels are instead a secondary consequence of primary effects of mHTT on the expression of 
regulatory proteins (Giacomello et al., 2013). 
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2.4.3 Sigma-1 receptor 
Communication between the ER and mitochondria is important for cellular survival. The ER 
supplies Ca2+ directly to mitochondria via inositol 1,4,5-trisphosphate receptors (IP3Rs) at close 
contacts between the two organelles called mitochondrion-associated ER membrane (MAM). 
Mitochondrial Ca2+ contributes to many physiological events, including bioenergetics, 
neuroplasticity, and cell death (Hayashi and Su, 2007). 
The sigma receptors are ER proteins classified into at least two subtypes; sigma-1 and sigma-2 
(Hayashi and Su, 2004). The sigma-1 receptor (Sig1R) has been cloned (Hanner et al., 1996) but the 
sequence of the sigma-2 receptor remains unknown. Hayashi and Su (Hayashi and Su, 2007) have 
shown that Sig-1R is a chaperone protein located at the MAM and forms a Ca2+-sensitive 
chaperone-complex with Bip prolonging Ca2+ signaling from ER into mitochondria by stabilizing 
IP3Rs. In nervous systems, Sig-1R also regulates neuritogenesis, K+ channels, memory, and drug 
addiction (Hayashi and Su, 2004; Hayashi and Su, 2007). Apart from the nervous system, Sig-1Rs 
are expressed in peripheral organs, including liver and pancreas, and in cancer cells (Hanner et al., 
1996; Vilner et al., 1995). 
Sig1R is upregulated by ER stress and overexpression of Sig1R is known to regulate UPR signaling 
(Hayashi and Su, 2007). It is also known that Sig1Rs can translocate from MAM to other parts of 
the ER, which could be provoked by ER stress. Knockdown of Sig1R was shown to promote 
apoptosis induced by ER stress and by oxidative stress (Hayashi and Su, 2007; Meunier and 
Hayashi, 2010). 
Previous studies have demonstrated potent anti-apoptotic actions of Sig-1Rs in neurodegeneration 
caused by β-amyloid and ischemia (Marrazzo et al., 2005; Vagnerova et al., 2006). Nevertheless, 
the basic molecular action of Sig-1Rs remains unknown and very little is known about its function 
in HD. Although the mechanisms involved in neuroprotective properties of Sig-1Rs are poorly 
known, stimulation of Sig-1Rs was reported to protect against oxidative stress. For example, 
siRNA-mediated Sig-1R knockdown decreased free radical scavenging activity in neuronal cell 
lysates (Tsai et al., 2009). Another study demonstrated that chloroquine, a widely used anti-malarial 
and anti-rheumatoid agent, at concentrations below its ability to inhibit autophagy and induce cell 
death, was able to rescue cells from glutamate-induced oxidative stress and cell death via Sig-1R 
(Hirata et al., 2011). Sig-1Rs are also suggested to play a critical role in the regulation of ROS 
levels. Sig-1R has also been shown to promote cell survival by transcriptionally regulating bcl-2 
expression via the ROS-inducible transcription factor NF-κB pathway (Meunier and Hayashi, 2010). 
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Although more studies are needed, Sig1-Rs may have therapeutic potential in treating oxidative 
stress-related neurodegenerative diseases.  
The level of Sig1Rs was shown to decrease in different neurodegenerative diseases. A postmortem 
study reported that Sig1Rs were reduced in the hippocampus in Alzheimer’s disease (Mishina et al., 
2008). Sig-1R protein levels were also decreased in the early Parkinson’s patients (Mishina et al., 
2005). Another study reported a novel mutation in Sig1R in the patients of juvenile Amyotrophic 
Lateral Sclerosis (ALS) (Al-Saif et al., 2011). Sigma-1R is also considered to be involved in aging, 
schizophrenia and depression (Mishina et al., 2008). 
Several selective Sig1R ligands have been synthesized, since the Sig1R binding sites were identified 
in 1982 (Su, 1982). Some of them have been shown to promote cellular survival by preventing 
oxidative stress caused by ischemia (Schetz et al., 2007), and by protecting from β-amyloid toxicity 
(Meunier et al., 2006). The compound PRE084 (2-(4-morpholino)ethyl1-phenylcyclohexane-1-
carboxylate hydrochloride) is a phencyclinide derivative and a highly selective ligand for the sigma-
1 receptor (Su et al., 1991). PRE084 has been shown to promote neuronal survival (Guzman-Lenis 
et al., 2009; Penas et al., 2011). A recent study reported that PRE084 also improves motor function 
and motoneuron survival in ALS mice (Mancuso et al., 2012).  
In a recent study immunohistochemical investigations were performed to clarify the localization of 
Sig-1R in the brains of patients with neurodegenerative disorders. The study showed that Sig-1R is 
consistently co-localized with neuronal nuclear inclusions in five polyglutamine diseases. The 
results indicated that Sig-1R shuttles between the nucleus and the cytoplasm, but during ER stress it 
relocates into the nucleus. Under normal conditions, HTT also shuttles between the ER and the 
nucleus, and regulates autophagy triggered by ER stress. However, mHTT loses its ability to return 
to the ER and starts to aggregate in the nucleus (Miki et al., 2013). 
 
2.5 Autophagy 
Autophagy is a process by which organelles and proteins are delivered in autophagosomal vesicles 
to the lysosomes for degradation. Autophagy is categorized to three different types; 
macroautophagy, microautophagy and chaperone-mediated autophagy (CMA) (Chen and Klionsky, 
2011). In macroautophagy, here referred to simply as autophagy, cytoplasmic components are 
engulfed by a double-membrane structure, the phagophore, which expand and fuses to form a 
double-membrane vesicle called the autophagosome. Autophagosomes fuse with lysosomes and 
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form autolysosomes, in which the content is degraded by hydrolases (Figure 5.) (Cheung and Ip, 
2011). The source of the isolation membrane is still unclear. It is generally believed to involve de 
novo membrane synthesis, but the ER, mitochondria, Golgi apparatus and plasma membrane have 
all been suggested as membrane sources for autophagosome formation (Hailey et al., 2010; 
Hayashi-Nishino et al., 2009; Ravikumar et al., 2010; van der Vaart and Reggiori, 2010; Yla-Anttila 
et al., 2009). Both microautophagy and CMA involve direct transport of cargo into the lysosomes. 
Microautophagy occurs through bulk sequestration of cytoplasmic content by lysosomes. CMA, on 
the other hand, requires direct transport of unfolded proteins into the lysosomes in a chaperone-
aided manner (Cheung and Ip, 2011). 
 
Figure 5. Macroautophagy is characterized by the formation of a cytosolic double-membrane vesicle, the 
autophagosome. During macroautophagy, cytoplasmic proteins, organelles or other materials are surrounded by 
phagophores, which expand and close to form autophagosomes. These autophagosomes fuse with lysosomes to 
form autolysosomes, in which the cytoplasmic cargos (mutant aggregated proteins or cellular organisms) are 
degraded by resident hydrolases.  LC3 localize to the phagophore throughout its elongation process. Upon 
completion of autophagosome formation, LC3-I dissociates from the membrane, whereas LC3-II remains on it. 
Autophagy can be inhibited by drugs such as 3-MA at the formation of autophagic vacuole stage (Sarkar and 
Rubinsztein, 2008). (Image modified from the original image of Melissa Cory) 
 
Although autophagy was generally considered to be nonspecific, however recent studies have 
revealed many examples of selective autophagy, including mitophagy (for mitochondria), ribophagy 
(for ribosomes), pexophagy (for peroxisomes) and reticulophagy (for the ER). There is a growing 
body of evidence, suggesting that the specificity factor for selective autophagy is determined by 
ubiquitination and binding of this ubiquitin signal by autophagic adaptor proteins (Shaid et al., 
2013). 
The primary role of autophagy is to protect cells under stress conditions, such as starvation. During 
periods of starvation, autophagy degrades cytoplasmic materials to produce amino acids and fatty 
acids that can be used to synthesize new proteins or are oxidized by mitochondria to produce ATP 
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for cell survival. Autophagy is also involved in cell growth, development and death. The levels of 
autophagy must be properly regulated, as indicated by the fact that dysregulated autophagy has been 
linked to many human pathophysiologies, such as cancer, myopathies and neurodegeneration (Chen 
and Klionsky, 2011). Neurons are particularly vulnerable to disruptions of autophagy, especially as 
the brain ages. Because neurons have unusually large expanses of dendritic and axonal cytoplasm, 
they face particular hurdles in preventing dysfunctional organelles and cellular waste from 
accumulating over a lifetime without the aid of cell division, which mitotic cells can rely on to 
dilute these waste burdens. (Nixon, 2013) Hence autophagy dysfunction leads to the accumulation 
of autophagic vacuoles and/or toxic protein aggregates, which can interfere with normal cellular 
functions. Initial studies have revealed the accumulation of autophagic vacuoles in the brains of 
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and HD patients (Ogata et 
al., 2006; Rubinsztein, 2006).  
 
2.5.1 Autophagy pathway 
The core molecular machinery that controls the different stages of autophagy is composed of 
proteins that are encoded by autophagy-related genes (ATGs). More than 30 of these genes were 
originally characterized in yeast, and many orthologs have subsequently been identified and 
confirmed as autophagy regulators in higher eukaryotes. Autophagy consists of four stages: 
initiation, elongation, maturation and fusion. The phagophore accumulates ATG proteins, which 
enables the membrane to elongate and form a double-membrane-bound structure called the 
autophagosome (Harris and Rubinsztein, 2011). To date, LC3-II is the best-identified mammalian 
protein species that specifically associates with autophagosome membranes (Kabeya et al., 2000). 
LC3 is a microtubule-associated protein light chain 3 (LC3), one of the mammalian Atg8 
homologues, and exists in two forms, LC3-I (18 kDa) and its lipidation form LC3-II (16 kDa), 
which are localized in the cytosol and in autophagosomal membranes, respectively. Another 
autophagy-related gene, Beclin 1, is the mammalian orthologue of yeast Atg6 and belongs to the 
class III phosphatidylinositol 3-kinase (PI3K) complex, which participates in autophagosome 
formation (Rami, 2009). 
Autophagy can be inhibited by different drugs. 3-methyladenine (3-MA) is a popular inhibitor of the 
autophagic pathway. 3-MA inhibits the activity of PI3K which blocks the formation 
autophagosomes (Liu et al., 2011). 
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2.5.2 Regulation of autophagy 
Autophagy is regulated by a complex network that consists of different signaling pathways. 
Simplified summary of the regulation of autophagy is illustrated in Figure 6. One important 
regulator of autophagy and ATGs is the mammalian target of rapamycin (mTOR) kinase. The 
mechanism by which mTOR regulates autophagy are not fully known, and this kinase controls 
several cellular processes besides autophagy. There are also other, mTOR-independent pathways 
that regulate autophagy (Williams et al., 2008). 
 
Figure 6. Simplified scheme of autophagy regulation. In the presence of amino acids, growth factors and 
energy, the mTOR complex 1 (mTORC1) represses autophagy by inhibiting the kinase activity of ULK1. In 
contrast, in the absence of amino acids and growth factors, or in response to an increase in the AMP/ATP ratio, 
via activation of AMPK, mTORC1 is inhibited and autophagy is initiated by the ULK1 complex. Atg proteins 
mediate the different steps of autophagy and LC3-II binds to autophagosome membrane to facilitate membrane 
elongation. Rapamycin and and the TSC1/2 complex inhibit mTOR. TSC1/2 mediates the inhibition by 
suppressing the mTOR regulator Rheb. Upstream of TSC1/2, AMPK activates AKT and inhibits TSC1/2 
activity via phosphorylation. Beclin 1 induces the autophagic vesicle formation in a complex with other co-
factors, like PI3K. Anti-apoptotic Bcl-2 and 3-MA inhibit Beclin 1 and PI3K activity. Autophagy inhibition by 
Ca2+ -dependent calpains is counteracted by calpain inhibitor calpastatin. Activators and inhibitors of 
autophagy are shown in blue and purple, respectively.  
 
2.5.2.1 mTOR-dependent signaling pathways 
The serine–threonine kinase mTOR is a master negative regulator of autophagy that acts by 
blocking the activity of the ULK1 complex that acts during initiation of autophagosome formation. 
The activity of mTOR depends on a variety of inputs from upstream signals that include the energy 
and nutrient status of the cell, as well as the presence of amino acids and growth factors. mTOR is 
inhibited when nutrients are scarce, growth factor signaling is reduced, and ATP concentrations fall. 
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Thus, under conditions of nutrient starvation, mTOR is inhibited and the repressive effect of mTOR 
on autophagosome formation is relieved, leading to enhanced autophagosome biogenesis. mTOR 
activity can also be inhibited by drugs (such as rapamycin) that promote autophagy (Harris and 
Rubinsztein, 2011). The mTOR pathway involves two functional complexes: mTORC1 (Figure 7.) 
consisting of mTOR, raptor (regulatory associated protein of mTOR), PRAS40, mLST8 and Deptor; 
and mTORC2 comprising mTOR, rictor, mLST8, Deptor, mSIN, and Protor1. The unique 
compositions of mTORC1 and mTORC2 determine the selectivity of their binding partners. Up to 
date we know more about mTORC1 rather than mTORC2 probably due to the lack of available and 
wide-spreaded inhibitors of mTORC2 activity. (Tchevkina and Komelkov Andrey, 2012) 
 
A major signalling cascade regulating mTOR activity is the class I PI3K pathway. The binding of 
growth factors or insulin to cell surface receptors activates the class 1a PI3K. Activated PI3K 
catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the plasma membrane, 
which increases the membrane recruitment of Akt/PKB and its activator PDK1, leading to the 
activation of Akt. The phosphorylation-dependent Akt activation results in the phosphorylation of a 
host of other proteins, including the tuberous sclerosis complex 1/2 (TSC1/TSC2). The TSC1/TSC2 
complex integrates upstream signals from various kinases, including AKT and ERK1/2 [16]. 
Phosphorylation of TSC2 by these kinases leads to the disruption of the heterodimer with TSC1, 
resulting in loss of TSC1/TSC2 activity. TSC1/TSC2 complex forms a functional complex that has 
GTPase-activating protein (GAP) activity toward Ras homolog enriched in brain (Rheb) to inhibit 
mTOR. Hence, the loss of TSC1/TSC2 activity results in mTOR activation and autophagy inhibition 
(Garcia-Arencibia et al., 2010; Kang et al., 2011). Cells with mutation in either TSC1 or TSC2 are 
hypersensitive to ER stress and undergo apoptosis (Kang et al., 2011). 
 
 
Figure 7. mTORC1 and TSC complexes. mTORC1 consists of mTOR, Raptor, PRAS40, mLST8 and Deptor. 
mLST8 binds to the mTOR kinase domain, where it seems to be crucial for their assembly. Deptor acts as an 
inhibitor. Phosphorylation inhibits the TSC1/2 complex, thereby relieving the TSC1/2-mediated repression of 
Rheb and allowing activation of TORC1. Modified from (Tchevkina and Komelkov Andrey, 2012) 
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mTOR can also act as a sensor of changes in cellular energy states via AMP-activated protein 
kinase (AMPK). AMPK is activated in response to low cellular energy (high AMP/ATP ratio). 
Activated AMPK downregulates energetically demanding processes like protein synthesis and 
stimulates ATP-generating processes such as fatty acid oxidation.  Activated AMPK directly 
phosphorylates TSC2 and thereby enhances its GAP activity, leading to the inhibition of mTOR 
signaling. AKT activates mTOR not only by direct phosphorylation of TSC2, but also by regulation 
of cellular energy by maintaining a high ATP level that causes a decrease in the AMP/ATP ratio 
that in turn inhibits AMPK-mediated phosphorylation and activation of TSC2 (Garcia-Arencibia et 
al., 2010; Wullschleger et al., 2006). 
2.5.2.2 mTOR-independent signaling pathways 
Pathways that act independently of mTOR can also regulate autophagy. For instance, in nutrient-
rich conditions, Beclin-1 is bound to the anti-apoptotic protein Bcl-2. On nutrient starvation (4h of 
starvation in Hank's balanced salt solution), the stress-activated enzyme JNK1 phosphorylates Bcl-2, 
which induces the dissociation of Bcl-2 from Beclin-1. Once dissociated, Beclin-1 can interact with 
other members of the autophagic machinery and stimulate the induction of autophagy. In nutrient-
rich conditions, Beclin-1 is bound to the antiapoptotic protein Bcl-2 (Harris and Rubinsztein, 2011; 
Wei et al., 2008).  
Another mTOR-independent pathway is cyclical and can be mediated by the cAMP-Epac-PLC-ε-
IP3 pathway and the Ca2+-calpain-G-stimulatory protein α (Gsα) pathway. PLC-ε-mediated 
generation of IP3 induces the release of Ca2+ from stores in the ER. High levels of intracytosolic 
Ca2+ inhibit autophagy by activating a family of Ca2+ cysteine proteases, calpains. After cleavage by 
calpains, Gsα becomes activated which, in turn, causes the production of more inhibitory cAMP. A 
decrease in IP3 is likely to result in reduced activity of IP3 receptors on the ER. Decreased levels of 
IP3 signaling leads to reduced Ca2+ release from the ER and lower rates of mitochondrial Ca2+ 
uptake, causing a small but effective reduction in mitochondrial activity and ATP levels, which 
results in AMPK activation. Activated AMPK directly phosphorylates ULK1, which leads to the 
induction of autophagy (Harris and Rubinsztein, 2011; Vicencio et al., 2009; Williams et al., 2008). 
Autophagy is also modulated by ROS. Starvation triggers accumulation of ROS, most probably 
H2O2, which is necessary for autophagosome formation and the resulting pathway of degradation. 
The oxidative signal is partially class I PI3K dependent. Treatment with antioxidants ameliorates 
the ability of starvation to induce autophagy.  One way in which ROS may be acting to regulate 
autophagy is by the modulation of the action of Atg4 on Atg8/LC3. The Atg4-mediated delipidation 
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of LC3-II on the cytosolic surface of autolysosomes allows it to be recycled. Atg4 is inactive and 
unable to cleave Atg8 from membranes when in its oxidized state. It is therefore possible that under 
oxidative conditions Atg4 is oxidized and inactive, which allows Atg8 to lipidate and thus initiates 
autophagy, while reduced Atg4 is active favoring Atg8 delipidation (Garcia-Arencibia et al., 2010; 
Scherz-Shouval et al., 2007). 
A recent study reported a function of Rhes, a striatal-specific protein implicated in the selective 
pathology of HD, in autophagy. In neuronal PC12 cells, deletion of endogenous Rhes decreased 
autophagy, whereas Rhes overexpression activated autophagy. These effects were shown to be 
independent of mTOR. Rhes bound the autophagy regulator Beclin-1 and decreased its inhibitory 
interaction with Bcl-2 independent of JNK-1 signaling. Mutant HTT blocked Rhes-induced 
autophagy activation (Mealer et al., 2013). 
2.5.2.3 GADD34 in autophagy  
GADD34 (Growth arrest and DNA damage-inducible gene 34) is a stress‐induced gene encoding a 
regulatory subunit of a protein phosphatase 1 (PP1) ‐containing complex that can dephosphorylate 
eIF2α in vitro and in vivo. GADD34 protein is induced by cell damage. (Novoa et al., 2003) 
GADD34 is a major regulator of translation during conditions of cell stress such as heat shock, virus 
infection, nutrient deprivation and exposure to agents that cause improper folding of proteins in the 
ER. Cells respond to stress by turning off protein synthesis through phosphorylation of eIF-2α, 
which also induces autophagy (Talloczy et al., 2002). Phosphorylated eIF-2α induces the expression 
of GADD34, which forms a functional complex with PP1 to dephosphorylate eIF-2α, which leads to 
the restoration of protein synthesis (Watanabe et al., 2007).  Studies of GADD34 gene deficient 
mice have shown that GADD34 promotes cell survival and the recovery from protein synthesis 
inhibition induced by ER stress (Kojima et al., 2003). 
Watanabe and colleagues proposed a novel pathway mediated by GADD34 that inhibits mTOR 
signaling and maintains translation during conditions of cellular stress. They showed that GADD34 
forms a stable complex with TSC1/2 and causes TSC2 dephosphorylation, which inhibits signaling 
by mTOR (Watanabe et al., 2007). Uddin and colleagues showed that GADD34 is induced by 
starvation and that it plays a critical role in the induction of autophagy mediated by inhibition of the 
mTOR signaling pathway (Uddin et al., 2011). GADD34 may find clinical potential as a drug target 
for the treatment of autophagy dysregulation associated diseases.  
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2.5.2.4 Ubiquitination and selective autophagy 
Ubiquitination is the hallmark of protein degradation by the 26S proteasome. Ubiquitin is a small 76 
amino acid polypeptide that was originally characterized as a covalently attached signal for ATP-
dependent proteasomal degradation of substrate proteins (Hershko and Ciechanover, 1998). 
Ubiquitin, a protein implicated in the proteasome degradation pathways, is also involved in selective 
autophagy. (Figure 8.) Identification of autophagy receptors, like p62/SQSTM1 and NBR1, which 
simultaneously bind both ubiquitin and autophagy-specific ubiquitin-like modifiers 
LC3/GABARAP, has provided a molecular link between ubiquitination and autophagy (Kirkin et al., 
2009). 
 
Figure 8. The Ubiquitin code links between proteasomal and lysosomal degradation. As illustrated, a 
misfolded protein can be degraded by proteasome or lysosomal system. Ubiquitinated misfolded protein is 
targeted for the proteasome. If the UPS is overloaded, protein aggregation occurs, which are then targeted for 
autophagic clearance. Thereby, ubiquitin chains on misfolded proteins can undergo remodelling by combined 
activity of deubiquitinating enzyme (DUB) and E3-ligases. Newly formed ubiquitin chains are then recognized 
by the UBD of p62, NBR1 or other autophagy receptors to form inclusion bodies or by the corresponding UBD 
of HDAC6, which direct protein aggregates to the aggresome. Aggresomes can be degraded via the proteasome 
or via autophagy pathway. If degradation occurs via autophagy, targeting of the protein aggregates are 
determined by the LIR motif of p62 and NBR1. LC3, light chain 3 protein; LIR, LC3-interacting region; Ub, 
ubiquitin; NBR1, neighbor of breast cancer 1; p62/SQSTM1, sequestosome 1; UBD, ubiquitin binding domain; 
UPS, ubiquitin–proteasomal system; HDAC6, histone deacetylase 6. Modified from (Shaid et al., 2013). 
 
Autophagy is considered selective when a precise cargo is specifically targeted into 
autophagosomes. This process involves ubiquitination (Shaid et al., 2013). The molecular 
characterization of ubiquitin binding proteins such as p62 and NBR1 (neighbour of breast cancer 1) 
has demonstrated that, analogous to the proteasome where ubiquitinated cargos are delivered by 
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ubiquitin receptors, an ubiquitin-dependent sensor system is responsible for substrate specificity. 
Before autophagic clearance, these receptors need to gather the ubiquitinated cargo to the nascent 
autophagosome, which carries LC3 or GABARAP (gamma-aminobutyric acid receptor-associated 
protein) proteins on its surface. Thus, autophagy receptors binding to both ubiquitin and LC3 or 
GABARAP proteins are able to control protein degradation by selective autophagy (Bjorkoy et al., 
2005; Weidberg et al., 2011). 
Filimonenko and colleagues showed that Alfy, a phosphatidylinositol 3-phosphate-binding protein, 
is required for the macroautophagic elimination of aggregated proteins, but not for macroautophagic 
elimination of bulk cytosol in response to starvation. Alfy was shown to function as a scaffold that 
gathers together the E3-like ligase (promoting protein-lipid conjugation), Atg5-Atg12-Atg16L, and 
LC3 to the target substrate to permit the degradation of mHTT proteins. Alfy overexpression 
decreased aggregated mHTT levels and protected cells from expanded polyQ toxicity in a primary 
neuronal HD model (Filimonenko et al., 2010)  
 
2.5.3 Autophagy in HD 
Autophagy was first demonstrated to have a protective role in neurodegeneration in a Drosophila 
model of HD. This study showed that activation of autophagy by the mTOR inhibitor rapamycin 
attenuated HTT toxicity (Ravikumar et al., 2004). In a cell model of HD, treatment with rapamycin 
reduced both the levels of soluble mHTT and the formation of intracellular aggregates of this 
protein, which protected cells against its toxic effects (Ravikumar et al., 2006). The mood stabilizer 
lithium induces autophagy. Lithium, a mood stabilizer drug, was shown to induce autophagy and 
enhance clearance of mHTT independently of mTOR through the inhibition of IP3 (Sarkar et al., 
2005). Autophagy inhibitors are known to increase the accumulation of transfected HTT in different 
types of cultured cells. For example, inhibition of autophagy in PC12 cells by 3-MA can raise the 
level of mHTT (Li et al., 2010).  
In mHTT expressing cells, the aggregates sequester mTOR, reducing the level of the soluble mTOR 
protein. This results in decreased mTOR activity, and a consequent increase in autophagy. This 
phenomenon seems to be confined to cells with aggregates, and is not seen in cells expressing 
soluble mutant protein. The ability of cells to induce autophagy when they contain polyQ aggregates 
may account for the observations that cells containing aggregates are less prone to cell death than 
cells expressing non-aggregated mutant polyglutamine proteins. This may be due to the more rapid 
 37 
 
clearance of the soluble protein in cells containing mHTT aggregates, leading to lower levels of 
diffuse HTT, which seems to correlate with lower toxicity and the protective effects of autophagy 
(Arrasate et al., 2004; Rubinsztein, 2006). Another study revealed aberrant cargo recognition in 
cellular and mouse model of HD. Detailed analysis indicated that despite normal autophagic flux, 
the autophagic vacuoles contain minimal cargo, thus resulting in a general decrease in protein 
turnover in different HD models (Martinez-Vicente et al., 2010). 
Beclin 1 has been shown to mediate the catabolism of mHTT. A study pointed out that the age-
dependent decline of beclin 1 expression and possible associated reduction of PI3K (III) is critical 
for the decline of autophagic function, which may lead to the accumulation of mHTT and the age-
delayed disease onset of HD. Furthermore, the study suggested that pharmacological means to 
increase of Beclin 1 function could be beneficial in delaying the onset as well as slowing the 
progression of HD (Shibata et al., 2006). 
Despite the observed neuroprotective effect of autophagy activation in different HD models, it still 
remains largely enigmatic how autophagy is impaired in HD (Cheung and Ip, 2011). The 
relationship between mTOR and autophagy in the clearance of mHTT is also complex. Inhibition of 
mTOR by drugs like rapamycin and lithium, which induce autophagy, are clearly beneficial in HD 
models. However, the clearance of mHTT by autophagy can occur in the presence of elevated 
mTOR activity but depends on Beclin-1, and separate studies demonstrated that mHTT 
accumulation is regulated by Beclin-1 (Yamamoto et al., 2006). Futher mentioned above, mHTT 
aggregates sequester mTOR, leading to decreased kinase activity and autophagy activation, 
presumably as a compensatory mechanism to cope with mHTT toxicity (Ravikumar et al., 2004).  
The gradual accumulation of mHTT affects the cellular processes involved in protein degradation, 
and as HD patients get older, these processes start to fail. This could also be the reason for the 
delayed onset of HD. Early in life, proteasomal degradation is robust and capable of preventing 
cytotoxicity. With advancing age, proteasomal function becomes compromised, forcing cells to rely 
more heavily on the autophagic pathway. Autophagic capacity also decreases with aging, which 
potentially leads to both normal aging and the pathologic aging seen in HD. Accordingly, in most 
tissues, the cytotoxic influences of mHTT are initially minimized by the proteasome before 
autophagy is required (Li and Li, 2011; Mealer et al., 2013). In the next chapter proteasomal 
degradation is discussed in more detail.  
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2.6 Proteasomal degradation 
With autophagy–lysosome pathway, the ubiquitin–proteasome system is one of the two main routes 
of protein and organelle clearance in eukaryotic cells. Protein degradation plays a central role in 
many cellular functions. The ubiquitin-proteasome system functions in cellular quality control by 
degrading misfolded, unassembled, or damaged proteins that could otherwise form potentially toxic 
aggregates (Li and Li, 2011).  
 
2.6.1 Ubiquitin-proteasome system 
The ubiquitin–proteasome system (UPS) is critical for cell survival and a variety of cellular 
functions. Altered UPS function can lead to a wide range of disturbances, such as cell degeneration. 
Dysfunction of the UPS has been implicated in the pathogenesis of many neurological diseases, 
including Alzheimer's disease, spinocerebellar ataxia, and several motor neuron diseases (Chen et 
al., 2009). 
Two sequential reactions are involved in protein clearance by the UPS: one is a tagging reaction and 
the other is a subsequent degradation of the tagged proteins in the proteasome (Figure 9.) (Li and Li, 
2011). Proteasomes are barrel-shaped multi-protein complexes that predominantly degrade short-
lived nuclear and cytosolic proteins. The 26S proteasome is a multicatalytic protease localized both 
in the nucleus and the cytoplasm. It is composed of three major subunits: one 20S catalytic core and 
two 19S regulatory caps. In the inner part of the 20S complex, there are three types of catalytic 
subunits that execute the corresponding catalytic activities of the proteasome (trypsin-like, 
chymotrypsin-like, and peptidylglutamyl-peptide hydrolyzing activity) (Li and Li, 2011). 
Most proteins are targeted for proteasomal degradation after being covalently modified with 
ubiquitin. This conjugation typically involves three types of enzymes: E1 (ubiquitin-activating 
enzyme) hydrolyses ATP and forms a thioester-linked conjugate between itself and ubiquitin; E2 
(ubiquitin-conjugating enzyme) receives ubiquitin from E1 and forms a similar thioester 
intermediate with ubiquitin; and E3 (ubiquitin ligase) binds both E2 and the substrate, and transfers 
the ubiquitin to the substrate. Frequently, the ubiquitin itself forms a substrate for further rounds of 
ubiquitination, resulting in the formation of a polyubiquitin chain. Chains of four or more ubiquitin 
molecules appear to form a recognition signal that allows substrates to be shuttled to the proteasome 
(Rubinsztein, 2006).  
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Figure 9. The Ubiquitin-proteasome system. First, a ubiquitin monomer is activated by forming an 
intermolecular thioester with the ubiquitin-activating enzyme (E1) in an ATP-requiring reaction. Next, 
activated ubiquitin is transferred to the active site of an ubiquitin-conjugating enzyme (E2). Finally, ubiquitin is 
linked in the substrate protein, a step that is catalyzed by an ubiquitin–protein ligase (E3). The E3 ligase 
confers specificity to the process by selectively binding to a protein target. Activated ubiquitin molecules are 
then sequentially added to the first ubiquitin proteins, forming a polyubiquitin chain. Proteins tagged with 
chains of four or more ubiquitins are then recognized by the 26S proteasome for degradation. After proteasome 
degradation, ubiquitin monomers are released or actively removed by the ubiquitin carboxyl-terminal 
hydrolases. Pi, inorganic phosphate; PPi inorganic diphosphate; Ub, ubiquitin.  
  
 
2.6.2 Proteasomal degradation in HD 
Multi-ubiquitylated proteins are usually efficiently degraded by proteasomes; hence the presence of 
elevated ubiquitin conjugates associated with protein aggregates in diseased neurons in nearly all 
neurodegenerative diseases has long suggested a linkage between UPS dysfunction and 
pathogenesis (Li and Li, 2011). In various cellular and animal models of HD, as well as in the 
postmortem brains of HD patients nuclear polyQ inclusions are positively labeled by antibodies 
against ubiquitin (DiFiglia et al., 1997; Gutekunst et al., 1999). Various studies indicate that the 
UPS is involved in processing both wild type and mHTT (Li et al., 2010; Roscic et al., 2011). 
Aggregates of mHTT are mainly present in the nucleus in human HD postmortem brains. As 
autophagy is a cytoplasmic degradation pathway, it is not sufficiently effective in clearing nuclear 
mHTT aggregates. To target nuclear aggregates, the UPS gets into the picture, as proteasomes are 
present in both the cytoplasm and nucleus (Schipper-Krom et al., 2012). 
It has been reported that protein aggregation can directly impair the function of the UPS. Transient 
expression of two unrelated aggregation-prone proteins, a HTT fragment containing a pathogenic 
polyQ repeat and a folding mutant of cystic fibrosis transmembrane conductance regulator, caused 
nearly complete inhibition of the UPS (Bence et al., 2001). Several studies have shown that 
inhibition of proteasome activity leads to accumulation of mHTT aggregates (Bence et al., 2001; 
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Wang et al., 2008). PolyQ-expanded proteins are found to impair UPS function in various cell 
models or in vitro systems, but in vivo studies of UPS function in polyQ disease mouse models have 
not yielded consistent results (Bence et al., 2001; Bennett et al., 2005; Bennett et al., 2007; Bett et 
al., 2006). Interestingly, misfolded polyQ proteins or filamentous mHTT can directly affect the 
function of proteasomes before the formation of inclusions in vitro. Thus, an important issue is 
whether UPS impairment also occurs in vivo (Bennett et al., 2005). Seo and colleagues examined 
postmortem brain tissues of HD patients and observed a decrease in proteasomal activity in the 
striatum and cortex. However, this decrease could be due to atrophy or degeneration already present 
in the HD patient brains (Seo et al., 2004). Wang and colleagues measured synaptic UPS activity 
and found a decrease in UPS activity in the synapses of HD mice (Wang et al., 2008). It is possible 
that the effect of polyQ proteins on UPS activity is dependent on its accumulation and subcellular 
localization, which cannot be detected by examining whole cell homogenates. Because UPS activity 
varies in different types of cells and in subcellular regions, it is important to evaluate UPS activity 
in different subcellular compartments of neurons (Wang et al., 2008). 
A recent study supported the finding that mHTT clearance is mediated by both proteasomal and 
lysosomal degradation. The study showed that overexpression of negative regulator of ubiquitin-like 
protein 1 (NUB1) reduced mHTT amounts by enhancing polyubiquitination and proteasomal 
degradation of mHTT. NUB1 showed mHTT-specific neuroprotection in the mammalian neuronal 
models as well as in an in vivo transgenic fly model (Lu et al., 2013). Another study has 
demonstrated that overexpression of the C terminus of Hsc70-interacting protein (CHIP) increase 
the ubiquitination and proteasomal degradation of mHTT and suppresses aggregation (Jana et al., 
2005). 
 
2.6.4 The deubiquitinating enzymes 
To maintain ubiquitin homeostasis, ubiquitin must be recycled once a substrate has been committed 
to the degradation pathway. Hence, both the proteasome and lysosomal sorting machinery have 
deubiquitylating enzymes (DUBs) associated with them (Clague et al., 2012; Komander et al., 2009). 
The human genome encodes approximately 100 DUBs that are predicted to be active and which 
oppose the function of E3 ligases (Komander et al., 2009). The largest of the five families is the 
ubiquitin-specific protease (USP) family (~55 members). The substrate specificity of DUBs is 
determined by sub-cellular localization, specific binding interactions and the preference of the 
catalytic domain for particular types of ubiquitin chain linkages (Clague et al., 2012). DUBs are 
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classified into five families: the USP (the ubiquitin-specific processing protease), UCH (the 
ubiquitin C-terminal hydrolyase), OTU (the ovarian tumor), MJD (the Josephin domain) and JAMM 
(the Jab1/Mov34 metalloenzyme) families. First four families are cysteine proteases, while the fifth 
family is metalloproteases, and to date USP and UCH are the best characterized families (Tian et al., 
2013). 
DUBs are thought to regulate three general processes: production of monomeric ubiquitin by 
cleaving ubiquitin from ubiquitin-fusion proteins; recycling ubiquitin from ubiquitin–protein 
conjugates at the proteasome; and editing ubiquitin chains to regulate ubiquitin chain length. A few 
DUBs have also been shown to associate with proteasomes. Both proteasome associated and non-
associated DUBs have been hypothesized to edit conjugated ubiquitin side chains and therefore, 
play an important role in regulating ubiquitin-signaling events such as protein stability and 
localization (Anderson et al., 2005). DUBs are crucial for various cellular functions and 
disturbances in these enzymes may lead to diseases in the nervous system (Singhal et al., 2008). 
Mutations in the DUB UCHL1 have been linked to an autosomal dominant form of PD. Oxidative 
modification and down-regulation of UCHL1 are associated with both PD and AD (Marshall et al., 
2013). 
2.6.4.1 Ubiquitin specific protease 14 (Usp14) 
Ubiquitin specific protease 14 (Usp14) is one of the DUBs. It functions at the proteasome to edit 
and/or remove ubiquitin chains (Borodovsky et al., 2001). Usp14 is expressed during 
embryogenesis and in adult tissues, including the nervous system (Chen et al., 2009; Crimmins et al., 
2009). 
Usp14 has been shown to be important for maintaining ubiquitin levels in neurons (Crimmins et al., 
2009). Through its association with the proteasome, Usp14 becomes catalytically active and 
deconjugates ubiquitin from substrates destined for proteasomal degradation (Chen et al., 2009; 
Crimmins et al., 2009). By facilitating ubiquitin recycling at the proteasome, Usp14 may act to 
stabilize ubiquitin pools at synaptic terminals (Chen et al., 2009). 
A mouse mutant with a spontaneous deletion of Usp14, the so called ataxia mouse (axJ), shows 
progressive neurological symptoms in the form of ataxia, tremor, hind limb paralysis and muscular 
weakness. These mice develop severe tremors by 2–3 weeks of age, followed by hindlimb paralysis, 
and death by 6–8 week (Anderson et al., 2005; D'Amato and Hicks, 1965; Wilson et al., 2002). 
While it is clear that the null mutant has a neurological phenotype, it remains unclear whether this is 
a non-specific (proteasomal) or more specific, non-proteasomal effect for Usp14 in neurons.  
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A recent study identified and characterized an N-ethyl-N-nitrosourea (ENU) induced mutation in 
Usp14 that leads to adult-onset neurological disease (nmf375 mice). The mutation causes aberrant 
splicing of Usp14 mRNA, resulting in a 95% reduction in USP14. The adult nmf375 mice exhibited 
deteriorating motor performance, depletion of monomeric ubiquitin and motor endplate disease, 
indicating that USP14 is required for stable maintenance of adult motor endplates and ubiquitin 
pools (Marshall et al., 2013). 
Usp14 might also have noncatalytic functions to modulate the degradation of proteins. Nagai and 
colleagues identified Usp14 as a binding partner of IRE1α. The interaction between IRE1α and 
Usp14 is inhibited by ER stress. Overexpression of Usp14 with the kinase negative form of IRE1α 
(IRE1αKN), which recruits Usp14 on the ER membrane, inhibits the degradation of unfolded ER 
proteins. Moreover, the inhibition of Usp14 expression by small interfering RNA (siRNA) resulted 
in enhanced of the degradation of unfolded ER proteins (Nagai et al., 2009). 
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3 AIMS OF THE STUDY 
This study elucidated the early pathological changes in HD.  The general aim was to study the role 
of ER stress, oxidative stress and autophagy in the cell models of Huntington’s disease. 
The specific aims of the study were: 
1. To study to role of GADD34 in the regulation of autophagy in a cell model of HD. (I) 
2. To study the role of Sigma-1 receptor and its agonist PRE084 in a cell model of HD. (II) 
3. Investigate the functions of Ubiquitin Specific Protease 14 (Usp14) in two different cell 
models of HD. (III) 
 
 
 
 
 
 
 
 
 
  
 44 
 
4 MATERIALS AND METHODS 
The detailed descriptions of the materials and methods are found in the original publications 
 
4.1 Cell cultures (I-III) 
4.1.1 PC6.3 cell cultures (I-III) 
PC6.3 cell line is a neuronal-like subline of PC12 pheochromocytoma cells from rat adrenal medulla 
that can be differentiated by NGF. These cells originate from the sympathoadrenal system and have 
several properties of the sympathetic neurons and are therefore considered as neuron-like cells. 
PC6.3 cells can be grown under conditions in which 90% of the cells undergo transcription-
dependent cell death following removal of NGF in either serum-free or serum-containing medium. 
PC6.3 cells are a good model system for characterizing cellular, biochemical and molecular events 
in programmed neuronal cell death (Pittman et al., 1993). In these studies PC6.3 cells were cultured 
without NGF.  
PC6.3 cells were cultured in cell culture dishes in RPMI-1600 (Lonza and Biochrom) medium 
supplemented with 5% fetal calf serum (Chemicon) and 10% horse serum (PAA), 7,5% NaHCO3, 
100mM Na-glutamine (Gibco) and 100mM penicillin-streptomycin.  
4.1.2 Hela cell cultures (III) 
Tetracycline (tet)-regulatable HeLa cell line stably express the first 17 amino acids of HTT followed 
by a polyQ expansion (65Q or 103Q) tagged with monomeric CFP (HttPolyQ-mCFP). As a control, 
we used cell lines that express 25 CAG repeats (25Q), which is under the aggregation threshold of 
37 repeats, and thus remains soluble. The cell line was created by co-transfecting HeLa tet-htt (25Q, 
65Q, or 103Q) exon1- mCFP and PTk-hygro (CLONTECH Laboratories, Inc.) and then selecting 
with hygromycin 800 μg/ml. Doxycycline (dox), belongs to tetracycline antibiotic class. Dox (100 
ng/ml) was also included in the culture media during selection to maintain suppression of transgene 
expression. HeLa cells were cultured in cell culture dishes in DMEM (Lonza) medium 
supplemented with 10% fetal calf serum (Chemicon), 7.5% NaHCO3, 100mM Na-glutamine (Gibco) 
and 100mM penicillin-streptomycin (Filimonenko et al., 2010; Yamamoto et al., 2006). 
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4.2 Animals (III) 
Animal experiments were done in collaboration with Dr. Petersén’s research group (Lund, Sweden). 
The BACHD model is a transgenic mouse expressing full-length mHTT that displays a metabolic 
phenotype and psychiatric-like behavior. The mouse was produced with the bacterial artificial 
chromosome-mediated transgenic approach and expresses full-length mHTT containing 97 
polyglutamine repeats. (Lundh et al., 2012) BACHD mice were obtained from the Jackson 
Laboratories ((FVB/N strain; Bar Harbor, Maine). All animal experiments were approved by the 
local ethical committee and accomplished in accordance with the European Communities Council 
Directive (86/609/EEC). We analyzed the tissue samples from BACHD mice received from Lund.  
 
4.3 Transfections and stimulations (I-III) 
PC6.3 cells were transfected with expression vectors encoding for different CAG-repeat (Q) lengths 
(18Q, 39Q, 53Q or 120Q) of huntingtin exon-1 fused to EGFP (Hasholt et al., 2003) or using full-
length huntingtin constructs with 17Q and 75Q repeats (a kind gift from Dr. Saudou). RFP-LC3 
(Red fluorescent protein- light chain 3 protein), EGFP-LC3 (Enhanced green fluorescent protein-
LC3), LAMP1-RFP (Lysosomal-associated membrane protein 1-RFP), Ubiquitin (RFP-Ub) and 
GADD34 expression plasmids were obtained from Addgene. Human wild type pRK-FLAG-USP14 
and mutant pRK-FLAG-USP14 C114A plasmids were a kind gift from Dr. Yihong Ye (Wang et al., 
2006). Transfectin reagent (Biorad) was used following the instructions provided by the vendor 
using 1 μg DNA per one well on 24-well plates, 3 μg DNA per one well on 6-well plates and 8 μg 
DNA per 10cm2 plates. Controls were transfected with EGFP expression plasmid (Clontech) and 
cells were incubated 24-48h prior to analysis.  
In some experiments, 1 mM or 5 mM 3-methyladenine (3-MA, Sigma), 20 µM MG-132 
(Calbiochem), 200 nM Rapamycin (Calbiochem), 2 μM thapsigargin (Sigma) or 1 μg/ml 
tunicamycin (Sigma) was added. LC3 immunoblotting was done in the presence of lysosomal 
proteasome inhibitors: 5 μM E64d (Sigma) and 10 μM pepstatin A (Sigma). In some experiments 
0.3 mM PRE084 (Tocris) and 3 mM progesterone (Sigma-Aldrich) were added 4 h after transfection.  
 
4.4 Immunoblotting (I-III) 
For immunoblotting cells were rinsed twice with ice-cold PBS and lysed in RIPA buffer (150 mM 
NaCl, 1 % Triton-X-100, 0,5 % sodium deoxylate, 1 % SDS, 50mM Tris-HCl, pH 7.4) 
supplemented with protease inhibitor cocktail (Roche) and phosphatase inhibitors (Phosphostop, 
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Roche). Protein concentrations were determined (BioRad BC assay) and equal amounts of protein 
(40μg) were subjected to SDS-PAGE and blotted onto nitrocellulose filters (Amersham), which 
were incubated for 1h in 5% skimmed milk or BSA, in TBS-T (50mM Tris-HCl pH 7.5, 150 mM 
NaCl, 0.1% Tween 20) and then with primary antibodies overnight at 4°C. After washing the filter 
was incubated with horseradish peroxidase-conjugated secondary antibodies (1:2500, Jackson 
ImmunoResearch Laboratories), followed by detection using enhanced chemiluminescence (Pierce). 
Immunoblots were quantified with ImageJ (NIH) quantification software. Primary antibodies used 
are shown in Table 3.  
 
4.5 Immunocytochemistry (I-III) 
HeLa and PC6.3 cells plated on poly-lysine and laminin coated coverslips were fixed for 7-20 min 
using 4% paraformaldehyde. Cells were incubated for 1 h using phosphate-buffered saline (PBS) 
containing 0.1% Triton-X-100 and 5% bovine serum albumin (Sigma), followed by overnight 
incubation in +4°C with primary antibodies. (Table 3.) Cells were washed using PBS and incubated 
for 1 h using Alexa Fluor 488 and/or 594 (1:500, Invitrogen Molecular Probes) or Cy5 (Jackson 
laboratories) secondary antibodies. Cells were counterstained for 1 min using Hoechst 33342 blue 
(4 mg/ml; Sigma), mounted in gel mounting medium (DABCO) and analyzed using a Zeiss LSM 
confocal microscope (Zeiss) at the Helsinki Biomedicum Molecular Imaging unit or by fluorescent 
microscope (Leica DM4500B).  
 
 
4.6 Immunoprecipitation (I, III) 
Cells were lysed in IP-lysis buffer (20mM HEPES-KOH, pH 7.5, 10mM KCl, 1.5mM MgCl2, 1mM 
EDTA, 1mM EGTA, 1mM DTT and 0.1mM PMSF) supplemented with protease inhibitor cocktail 
(Roche) and PhosphoStop (Roche). Protein concentrations were measured with Bio-Rad protein 
assay (BCA protein assay kit) and equal amounts of proteins (typically 200-300μg) were taken for 
immunoprecipitation. Pre-clearing was done by incubating the lysates with protein A- and G-
agarose beads (Roche) followed by an overnight incubation in +4°C with either Usp14 (III) or 
GADD34 (I) antibodies. Following day 50 μl of protein G-agarose was added and incubated in a 
rotor at +4°C for 2 hours. Agarose beads were collected by centrifugation and washed three times 
with lysis buffer. The agarose pellet was dissolved to 50μl of 1xWB loading buffer and boiled for 
10 min followed by centrifugation, at 14000 rpm for 5 min. Subsequently, immunoprecipitates were 
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BRL). Incubation was carried out at 42°C for 55 min in 20mM Tris-HCl (pH 8.4), 5mM MgCl2, 
500μM dNTPs, and 10mM DTT in a final volume of 20 μl.  
PCR reactions were started with a 5 min denaturation step at 95 °C followed by 30 cycles carried 
out at 95°C for 60 s, 63°C for 60 s and 72°C for 90 s. The following primers were used: GADD34: 
5′-GTCCATTTCCTTGCTGTCTG-3′ (forward), 5′-AAGGCGTGCCCATGCTCTGG-3′ (reverse). 
ß-actin: 5′- CTTCAACACCCCAGCCATG-3′ (forward); 5′-GTGGTACGACCAGAGGCATAC- 3′ 
(reverse). 
4.8.1 Reverse transcription and quantitative PCR (II) 
Total RNA was extracted from cells using the GenElute Mammalian total RNA kit (Sigma) and 
gene-specific reverse transcription was performed using Tetro reverse transcriptase (Bioline). cDNA 
synthesis was carried out in a 10-ml reaction volume containing Tetro reaction buffer, 0.5 mM each 
of the reverse primers (calpastatin, 5’-CCCCAGTAGACTTCTCTTTC-3’ ; Sig1R, 5’-
CTTCCTCTACATTC CTCTG-3’), 750 ng of the RNA template and 0.5 ml Tetro reverse 
transcriptase. The reaction was incubated at 75°C for 5 min to open RNA secondary structures, and 
samples were cooled to 42°C. Superscript III reverse transcriptase was then added and the samples 
were incubated at 42°C for 20 min followed by enzyme inactivation at 64°C for 20 min. The 
unbound reverse transcription primers were digested with 20 units Exonuclease I (New England 
Biolabs GmbH) at 37°C for 30 min, followed by denaturation at 80°C for 15 min. One microliter of 
product was then amplified with Light Cycler 480 SYBR Green I Master Mix (Roche Diagnostics 
GmbH, Mannheim, Germany) and using 0.5 mM of forward (fw) and reverse (rev) primers 
(calpastatin, fw: 5’-AGT AGTTCTGGACCCAATG-3’ , rev: 5’-CCCCAGTAGACTTCTCTTTC-
3’; Sig1R, fw: 5’-TGCCTTATCTCCATTCCA-3’, rev: 5’-CTCCTTCCTTCAGTCCTT-3’). qPCR 
amplification and relative quantification was performed on the LightCycler 480 II instrument 
(Roche) with 40 cycles (10 s denaturation at 95°C, 20 s annealing at 60°C and 20 s extension at 
72°C). Melting curve acquisition and analysis was also carried out immediately after amplification 
to confirm the specificity of PCR. 
 
4.9 Autophagy detection (I) 
PC6.3 cells were transfected with different huntingtin constructs together with RFP-LC3 and fixed 
after 24 h or 48 h using 4% paraformaldehyde. The number of cells with LC3 positive vesicles was 
analyzed. Cells with more than five dots were considered positive.  
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Conversion of LC3 was also studied using immunoblotting and the appearance of the lower LC3-II 
band was used as an indication of autophagosome formation. Experiments were done with and 
without lysosomal proteasome inhibitors, E64d (Sigma) and pepstatin A (sigma). In the absence of 
lysosomal protease inhibitors we were able to measure the lysosome-dependent degradation.  
Autophagy flux was also detected by transfecting the cells with different huntingtin constructs 
together with GFP-LC3(B). When GFP-LC3 is delivered to a lysosome the LC3 part of the chimera 
is sensitive to degradation, whereas the GFP protein is relatively resistant to hydrolysis. Therefore, 
the appearance of free GFP on western blots can be used to monitor lysis of the inner 
autophagosome membrane and breakdown of the cargo (Klionsky et al., 2008). 
 
4.10 Solubility assay (II-III) 
Cells were lysed in solubility buffer containing 50 mM Tris-HCl, pH 7.5, 100 mM NaCl2, 3 mM 
EGTA, 0.5% Triton X and protease inhibitors (Roche) and kept on ice for 5 min. Aliquotes (30 μl) 
of the extract were mixed with 10 μl 4× sodium dodecyl sulfate (SDS) loading buffer and sonicated 
(total cell lysate). The remaining cell lysate was centrifuged at 13 000 g for 10 min, and the 
supernatant was mixed with 4× SDS loading buffer (soluble fraction); the pellet was dissolved in 1× 
SDS loading buffer and sonicated (insoluble fraction). Equal amounts were then analyzed on SDS–
PAGE gel and subsequent WB using a monoclonal GFP antibody (Roche) and horseradish 
peroxidase-coupled anti-mouse secondary antibodies (Jackson). To detect high molecular weight 
forms of the huntingtin fragment proteins, the stacking gel was also blotted. 
 
4.11 Luciferase reporter assay (II) 
The Luciferase Assay System is a reporter quantitation assay that can be used to study gene 
expression. The luciferase assay kit is based upon the bioluminescent measurement of firefly 
luciferase. The intensity of light emission is linearly related to the amount of luciferase and is 
measured using a luminometer.  
PC6.3 cells in six-well plates were transfected with 0.5 mg of full-length huntingtin expression 
plasmids in conjunction with 0.5 mg of the NF-κB reporter plasmid, containing multiple NF-kB 
sites linked to firefly luciferase gene. A volume of 0.02 mg of Renilla luciferase (pRL-TK) was 
used to control for transfection efficiency. Cells were harvested 48h after transfection and lysed to 
Passive Lysis Buffer (Promega). For assaying the expression of Renilla and firefly luciferase we 
used the dual lusiferase substrate and the activities were measured by luminometer (GloMax 
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TD20/20 Luminometer Turner Designs). Results are shown as fold increase in luciferase normalized 
to the Renilla activity. 
 
4.12 Caspase assay (II) 
PC6.3 cells were transfected with HTT 18Q- and 120Q-expressing plasmids as noted above and 0.3 
mM PRE084 was added 4 h after transfection as indicated. Controls were transfected with EGFP 
expression plasmid. Cells were incubated for 2 days and caspase-3/7 activities were measured using 
a Caspase-Glo assay kit (Promega) as described by the vendor. Samples were incubated at room 
temperature for 90min and the luminescence was measured using a luminometer (GloMax TD20/20 
Luminometer Turner Designs). 
 
4.13 Cell degeneration assays (I-III) 
Hoechst 33342 (Sigma) was employed to stain dying cells showing condensed and fragmented 
DNA (Korhonen et al., 2005; Sokka et al., 2007).  More than 300 fluorescent cells in each well were 
analyzed and experiments were repeated three times. Results are expressed as percentage of 
transfected cells. 
 
4.14 Measurements of intracellular ROS (II) 
PC6.3 cells were cultured in 96-well plate and transfected with flHTT constructs with 17- and 75 
polyglutamine repeats for 48 h, 0.3 mM PRE084 was added 4 h after transfection. Cells were treated 
with 10 mM 6-carboxy-20,70-dichlorodihydrofluorescein diacetate, di(acetoxymethyl ester) 
(H2DCFDA AM: Invitrogen, Carlsbad, CA, USA) and incubated at 37°C for 45 min. H2DCFDA is 
able to penetrate cells due to the acetoxymethyl ester, where it is hydrolyzed by intracellular 
esterases to form 20,70-dichloro-fluorescin (DCFH). Oxidation of DCFH by hydrogen peroxide and 
hydroxyl radicals yields a highly fluorescent product 20,70-dichlorofluorescein (DCF). The 
fluorescence intensity of DCF after excitation of the samples at a wavelength of 485 nm was 
measured at an emission wavelength of 535 nm using a fluorescence microplate reader. Results are 
shown as normalized to control (set to 100%). 
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4.15 Measurements of intracellular calcium (II) 
PC6.3 cells were grown on poly-L-lysine-coated coverslips and transfected for 24h as described 
above. Cells were then washed three times with HBSS buffer (118mM NaCl, 4.6mM KCl, 1mM 
CaCl2, 10mM D-glucose, 20mM HEPES, pH 7.4), following a 30-min incubation with 2 mM Fura-
2 AM at room temperature. After washing twice using HBSS, the cells were transferred to a heated 
coverslip holder adjusted to 37 1C, and perfused with HBSS containing 100 nM bradykinin. An 
XBO 75W/2 xenon lamp served as the source for excitation light and the excitation filters were set 
at 340 or 380 nm, respectively. Emitted light was measured at 510 nm. Filters were controlled with 
Lambda 10-2 (Sutter Instruments). A SensiCam CCD camera was employed for image acquisition 
and the recorded images were processed using the Axon Imaging Workbench software (Axon 
Instruments). The F340/F380 fluorescence ratio served as the indication of intracellular calcium 
concentrations. 
 
4.16 Aequorin-based measurements of mitochondrial calcium (II) 
Measurements of mitochondrial Ca2+ concentration ([Ca2+]mito) were carried out using recombinant 
aequorin targeted to mitochondrial matrix (mtAeq) and a luminometer system as described 
previously. (Brini et al., 1995; Brini, 2008) In brief, cells were grown to 70% confluency on poly-L-
lysine-coated 13-mm glass coverslips and transfected with the mtAeq (kind gift from Professor U 
Ruegg, Geneva, Switzerland) along with control (pcDNA), 17Q- or 75Q-huntingtin-expressing 
plasmids as described previously. At 24h after transfection, the cells were washed with HBSS buffer 
(118mM NaCl, 4.6mM KCL, 1mM CaCl2, 10mM D-glucose, 20mM HEPES, pH 7,4) and 
reconstituted with 5 mM native coelenterazine (Invitrogen) for 1h at room temperature. PC6.3 cells 
were then placed into a perfusion chamber and the luminescence was recorded. All measurements 
were conducted in HBSS at 37°C. Cells were stimulated with 100 nM bradykinin (Sigma-Aldrich) 
to induce the release of Ca2+ from the intracellular stores. Calibration of the measurements was done 
by permeabilizing the cells in HBSS containing 10 mM Ca2+ and 100 mM digitonin (Sigma-
Aldrich), thus generating the maximal luminescence of the sample. Luminescence data was then 
converted to [Ca2+] according to Brini et al. (Brini et al., 1995). 
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4.17 Determination of cell viability with MTT assay (I-II) 
Cell viability was determined by the MTT [3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium 
bromide (Calbiochem) assay (Sigma). PC6.3 cells were transfected with different plasmids for 24-
48h. Cells were incubated in the presence of MTT solution (Thiazolyl blue tetrazolium bromide, 
Sigma) for 2 h at 37°C. After incubation the medium (containing MTT) was removed. 40 mM HCl 
in isopropanol was added to solubilize the dye absorbed by the cells. The amount pf the dye was 
measured by absorbance at 560 nm with Labsystems Multiskan MS spectrophotometer. The 
absorbance was linear to the number of viable cells.  
 
4.18 Statistical analyses (I-III) 
All experiments were repeated at least three times. Statistical comparison was performed using 
student’s t-test or one-way ANOVA and a bonferroni post hoc test. P value p < 0.05 was considered 
as statistically significant.   
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5 RESULTS AND DISCUSSION 
 
5.1 GADD34 plays an important role in cell protection in mHTT expressing 
cells by increasing autophagy and cell survival. (I) 
The pathophysiological changes in HD are complex and include alterations in gene transcription, 
cell signaling, energy metabolism, protein trafficking, transport and synthesis, as well as an 
impaired degradation of misfolded and aggregated proteins. The precise signals regulating these 
events are not fully understood but ER stress and changes in autophagy are proposed to be involved 
in the cell degeneration observed in HD (Duennwald and Lindquist, 2008; Levine and Kroemer, 
2008). 
5.1.1 Mutant HTT expression induces autophagy and inhibits the mTOR pathway in 
neuronal PC6.3 cells  
24 h after transfection, expression of N-terminal mHTT fragment proteins, containing 120 
polyglutamine repeats (120Q), increased the phosphorylation of eEF2 and eIF2 in neuronal PC6.3 
cells, reflecting an inhibition of global protein synthesis (I/Fig.1A). The translational block is not 
absolute as the proteins ATF4 and CHOP, involved in cell protection and ER stress, were 
synthesized (I/Fig.1C).  
Phosphorylation of p70 S6K and Akt was decreased in mHTT expressing cells (I/Fig.1E-F).  p70 
S6K is a target for the mTOR kinase in cells and the decreased phosphorylation correlates with 
mTOR inhibition. Akt activates mTOR not only by direct phosphorylation of TSC2, but also by 
regulation of cellular energy. Akt maintains a high ATP level that causes a decrease in the 
AMP/ATP ratio that in turn inhibits AMPK-mediated phosphorylation and activation of TSC2 
(Wullschleger et al., 2006). 
Our data showed that the number of LC3 positive autophagosomes was increased in mHTT (120Q) 
expressing cells compared with control and wt HTT (18Q) expressing cells showed by RFP-LC3 
and staining for endogenous LC3 (I/Fig.2A and Fig.2D). Quantification showed that the number of 
autophagosome positive cells increased significantly in N-terminal mHTT fragment proteins 
expressing cells as well as in cells expressing the disease-causing FL mHTT (75Q) proteins 
(I/Fig.2B). Also immunoblotting for endogeneous LC3, with and without lysosomal inhibitors, 
showed a conversion of LC3 (LC3-I to LC3-II) in mHTT expressing cells (I/Fig.2C). These results 
indicated that mHTT protein expression induces autophagy 24 h after transfection.  
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5.1.2 GADD34 interacts with tuberous sclerosis complex (TSC) proteins in mHTT 
expressing cells and mediates mTOR inhibition  
Previous studies have shown that the inhibition of mTOR pathway by using rapamycin can reduce 
cell toxicity induced by mHTT (Ravikumar et al., 2004). However, little is known about the 
upstream mechanisms controlling mTOR in neurodegenerative diseases, including HD. 
GADD34 plays an important role in the control of protein synthesis after global translation block; it 
interacts with PP1 and dephosphorylates eIF2α, which stimulates protein synthesis during cell 
injury (Harding et al., 2000; Novoa et al., 2003). GADD34 inhibits protein synthesis via the TSC 
protein complex that is also involved in the control of neuronal responses to stress (Di Nardo et al., 
2009; Watanabe et al., 2007). The loss of TSC1 or TSC2 triggers the UPR in the ER (Ozcan et al., 
2008). Interestingly, we observed largely intact levels of TSC1 or TSC2 in mHTT expressing cells 
at 24h, when the ER stress pathways are already activated (Reijonen et al., 2008). This probably 
reflects the nature of the upstream signals that activate UPR and ER stress in different cell types.  
The TSC complex, consisting of the TSC1 and the TSC2 proteins, regulates mTOR and the complex 
has emerged as a critical integrator of growth factor, nutrient and stress signals to control protein 
synthesis, cell growth and other cellular processes (Huang and Manning, 2008). Phosphorylation of 
TSC2 by upstream kinases, such as Akt, inhibits the activity of this complex and reduces mTOR 
signaling.  Dephosphorylation of TSC2 by various phosphatases, on the other hand, inhibits mTOR 
and activates autophagy. GADD34 is engaged in dephosphorylation reactions and was previously 
shown to interact with the TSC complex (Watanabe et al., 2007).   
GADD34 levels may increase during cell stress, but little is known about the precise temporal 
changes of GADD34 after various insults. Our data showed that the expression of GADD34 was not 
significantly changed 24 h after transfection with mHTT constructs as determined by semi-
quantitative PCR and immunoblotting, neither was the subcellular localization of GADD34 altered 
in mHTT expressing cells (I/Fig.3A-B). However, immunoprecipitation showed that GADD34 
specifically interacted with TSC1 in mHTT (120Q) proteins expressing cells 24 h after transfection  
but not in cells expressing wt HTT and empty EGFP-vectors (I/Fig.3C). The binding of GADD34 to 
TSC1 may stabilize the TSC-complex, as shown previously for GADD34 in non-neuronal cells 
(Inoki et al., 2002). It remains to be studied whether GADD34 may specifically interact with mHTT 
and other polyQ proteins. 
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By binding to TSC-complex GADD34 may inhibit mTOR signaling 24h after mHTT transfection 
(I/Fig.3D). In line with this, the phosphorylation of mTOR was decreased in mHTT (120Q) 
expressing cells 24 h after transfection but not 48 h transfection. (I/Fig.3D-E).  
5.1.3 Autophagy is inhibited at 48h in mHTT expressing cells - relationship to changes 
in GADD34 levels and AMP-activated protein kinase (AMPK) activity  
In contrast to the situation 24 h after mHTT transfection, we observed that the protein levels of 
GADD34 were downregulated in mHTT (120Q) expressing cells 48 h after transfection (I/Fig.4A-
B). This effect seemed to be dependent on mHTT since treatment with two well-known ER stress 
inducers, tunicamycin and thapsigargin, did not have an effect on GADD34 protein levels (I/Fig.4C). 
The decrease in GADD34 at 48 h was accompanied by an increase in the phosphorylation of TSC2 
that in turn leads to activation of mTOR (I/Fig.3D) and to the inhibition of cytoprotective autophagy 
(I/Fig.4J-K). In line with this, we observed that there was a restoration in the phosphorylation of 
p70S6K and Akt in mHTT (120Q) expressing cells 48 h after transfection (I/Fig.4F-H). The 
decrease in GADD34 48 h after transfection contrasts to the situation at 24h and is probably due to 
an inhibition of protein synthesis that ultimately reduces GADD34 levels in mHTT expressing cells. 
It has been known for some time that another important cellular energy sensor, AMPK, can play a 
role in autophagy induction by phosphorylating TSC2 to inactivate mTOR (Wong et al., 2013). This 
let us to study the activity of AMPK in mHTT expressing cells. Our data showed that AMPK was 
activated in mHTT expressing cells at 24 h as shown by phosphorylation of its substrate Acetyl-
CoA carboxylase (ACC) (I/Fig.4I). This indicates that AMPK may contribute to cytoprotective 
autophagy at early time points in mHTT expressing cells. However at 48 h the AMPK activity 
decreased that may lead to an increase in mTOR and an inhibition of autophagy in these cells 
(I/Fig3D). To study this more directly, we stained for LC3 positive autophagosomes in mHTT 
expressing cells at 48 h (I/Fig.4J). Quantification showed that the number of autophagosome 
positive cells was low in both wt cells and in those expressing either the N-terminal mHTT 
fragment protein or the disease-causing flHTT protein (I/Fig.4K). This data is in contrast to results 
obtained at 24 h, indicating that the lack of autophagy at 48 h may contribute to the deleterious 
effects of the HTT protein at longer time points. 
5.1.4 Overexpression of GADD34 enhance autophagy and protects cells against 
mHTT-induced cell degeneration  
Our results indicate that GADD34 may be an important regulator of mTOR and autophagy in 
mHTT expressing cells. To study this further, we overexpressed and downregulated GADD34 in 
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neuronal PC6.3 cells and analyzed the effects on the activity of the TSC/mTOR pathway and on 
autophagy. Our data showed that overexpression of GADD34 increased the dephosphorylation of 
TSC2 in mHTT expressing cells at 48 h (I/Fig.5B). GADD34 overexpression also activated 
autophagy in cells expressing the wt HTT as well as the disease-causing FL mHTT protein at 48 h, 
shown by immunoblot (I/Fig.5D).  
The elevated autophagy increased cell viability in mHTT expressing cells as shown by MTT assay 
(I/Fig.5E). Our data showed that mHTT (120Q) protein expression induced caspase-3 and PARP (a 
substrate for caspase-3) cleavage. GADD34 overexpression reduced the cleavage of Caspase-3 and 
PARP (I/Fig.5G,F). Silencing of endogenous GADD34 increased caspase-3 activation and cell 
viability (I/Fig5E-G,F). Also cell viability was abolished by GADD34 silencing (I/Fig.5E). This 
data linked the expression levels of GADD34 to cell death and to the susceptibility of neuronal 
PC6.3 cells to undergo cell degeneration after expression of mHTT proteins. 
To further elucidate the role of autophagy in cytoprotection, we showed that the autophagy inhibitor 
3-MA, significantly decrease the viability in mHTT expressing cells (I/Fig.5). This indicates that an 
unperturbed autophagy mediates protection against cell degeneration induced by mHTT proteins in 
the neuronal PC6.3 cells. These results demonstrate that inhibition of autophagy cause cell 
degeneration in neuronal PC6.3 cells. Previous data also support the view that active autophagy may 
facilitate the removal of misfolded proteins, and other toxic products and damaged organelles 
during cell stress (Levine and Kroemer, 2008; Ogata et al., 2006). 
 
Figure 10. Summarizing figure.  
 
Autophagy has been linked to increased cell survival after ER stress and autophagy observed here 
probably serves as a protective measure against the deleterious effects of mHTT protein and thus is 
a cell protective signal (Ogata et al., 2006). This study showed that mHTT proteins regulate the 
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mTOR pathway in neuronal PC6.3 cells with a decrease in protein synthesis and time-dependent 
change in the process of autophagy. GADD34 binds TSC1 and dephosphorylates TSC2, which leads 
to the inhibition of mTOR activity and induced cytoprotective autophagy. However, autophagy was 
inhibited at later time points in mHTT expressing cells. Overexpression of GADD34 prolonged the 
inhibition of mTOR and stimulated autophagy and thereby protected cells from mHTT induced cell 
death. These data underscore the importance of autophagy in the pathogenesis of HD (Figure 10.).  
 
5.2 Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-
induced cell degeneration: involvement of calpastatin and the NF-κB pathway 
(II) 
Alterations in mitochondria and increased oxidative stress are associated with the disease 
progression in HD (Federico et al., 2012). ER stress and oxidative damage are linked through the 
close communication between the ER and mitochondria (Hayashi and Su, 2007). Sig-1R is a 
chaperone protein in the ER that is involved in ER stress regulation, but little is known about its role 
in HD or the mechanisms for cell protection. In this work, we studied the role of Sig-1R and its 
agonist 2-(4-morpholinoethyl)-1-phenylcyclohexane-1-carboxylate hydrochloride (PRE084) in a 
cellular model of HD with overexpression of wt and mHTT in neuronal PC6.3 cells. 
Sig-1R has been linked to neurodegenerative disorders as shown by analyses of materials from 
patients afflicted by these diseases. A postmortem study reported that Sig-1Rs were reduced in the 
hippocampus in AD and Sig-1R levels were also decreased in specimens from patients with early 
Parkinson’s disease (Mishina et al., 2005; Mishina et al., 2008). The mechanisms involved and the 
functional significance of these changes, however, are not fully understood.  
Sig-1R protein levels were decreased in the total cell lysates after expression of mHTT proteins, but 
restored by the agonist PRE084 (II/Fig.1A-D). In cells, Sig-1R is largely localized in the ER in the 
MAM sub-compartment, which links it close to the mitochondria (Hayashi et al., 2009). We 
observed a partial co-localization of Sig-1R with aggregates in mHTT expressing cells, suggesting 
that the Sig-1R may be redistributed or delocalized in these cells (Figure 11). This has been shown 
also by others (Miki et al., 2013). The agonist PRE084 is thought to stabilize Sig-1R and may 
therefore hinder its relocalization to protein aggregates containing mHTT proteins. However more 
studies are required to reveal the precise mechanisms by which PRE084 affects the cellular 
functions of Sig-1R in neuroprotection. 
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Figure 11. Confocal microscopy.  Immunofluorescence (green) of PC6.3 cells transfected for 24 h with HTT 
fragment proteins containing 18Q (upper panels) and 120Q repeats (middle panels). Immunostaining was done 
using specific antibody against Sig-1R (red fluorescence). Sig-1R is present in part in cytoplasmic aggregates 
in cells expressing120Q-HTT in the merged picture (yellow color). Lower panels, immunostaining using the 
EM48 antibody recognizing mHTT aggregates. Note a partial co-localization with Sig-1R. Scale bar 15 mm. 
 
5.2.1 The Sig1-R agonist PRE084 counteracts mHTT induced cell death and caspase 
activation  
In this study we investigated whether the Sig-1R has a role in cell degeneration. Expression of N-
terminal mHTT proteins in PC6.3 cells has been shown to lead to cell death characterized by 
activation of various caspases (Reijonen et al., 2008; Reijonen et al., 2010). 
Several selective Sig-1R ligands have been synthesized since the identification of the Sig-1R-
binding sites (Maurice and Su, 2009; Su, 1982). Pharmacological studies have shown that such 
ligands may have many physiological effects ranging from neuroprotection to neuropsychiatric and 
anti-depressant effects (Hayashi and Su, 2004; Kourrich et al., 2012; Walker et al., 1990). The 
PRE084 was shown to have beneficial effects in various models of brain diseases including 
neurodegenerative and acute brain disorders. PRE084 was shown to promote cell survival and 
reduce oxidative stress caused by ischemia and toxicity induced by β-amyloid peptide (Marrazzo et 
al., 2005; Schetz et al., 2007). PRE084 was also neuroprotective against nerve avulsion injury and it 
acted on motoneurons both in vivo and in vitro (Guzman-Lenis et al., 2009; Mancuso et al., 2012; 
Penas et al., 2011). 
Our results showed that PRE084 protected neuronal PC6.3 cells against mHTT induced cell 
degeneration (II/Fig.2A-G).  PRE084 counteracted caspase-3 cleavage that was induced by mHTT 
and reduced the cleavage of PARP that is a target for the active caspase-3 (II/Fig.2C). Previous 
 60 
 
studies have shown that procaspase-12, which resides in the ER is cleaved in cells expressing the 
120Q-HTT fragment proteins. (Reijonen et al., 2008) Our results showed that PRE084 also 
prevented the cleavage of caspase-12 in mHTT cells, suggesting a cytoprotective effect of PRE084 
related to reduced ER stress (II/Fig.2F-G).  
5.2.2 Stimulation with PRE084 increases cellular antioxidants and reduces ROS in 
mHTT expressing cells 
Sig-1R is present in MAM and stabilizes the IP3R1 (Hayashi and Su, 2007). Furthermore, mHTT 
can interact with ER and modulate calcium signaling in HD (Bezprozvanny, 2011; Higo et al., 2010; 
Reijonen et al., 2010). Using the mitochondrial calcium reporter aequorin, we showed that neither 
PRE084 nor expression of mHTT proteins influenced [Ca2+] in mitochondria in the PC6.3 cells 
(II/Fig.3A-D). This is an important observation, as deregulation of mitochondrial [Ca2+] may in turn 
lead to an increased ROS production by this organelle with deleterious functional consequences 
(Decuypere et al., 2011). PRE084 did not directly affect the mitochondrial [Ca2+] in mHTT 
expressing cells compared with controls (II/Fig.3A-D). However, PRE084 did have an effect on the 
mitochondria-localized antioxidants. We stimulated cells expressing 120-huntingtin fragment 
protein with PRE084. The immunoblotting results showed that PRE084 was able to increase the 
cellular levels of various antioxidants that were downregulated by the 120Q-huntingtin (II/Fig.4A-
E). Along this line, stimulation of PC6.3 cells with PRE084 reduced intracellular ROS levels that 
were elevated by the disease-causing 75QFL huntingtin protein (II/Fig.4F). Consequently PRE084 
seems to be able to decrease the levels of ROS and oxidative stress in neuronal PC6.3 cells 
expressing mHTT proteins via the upregulation of cellular antioxidants. 
5.2.3 PRE084 increases NF-B-p65 levels and activate NF-B-p65 signaling in 
neuronal PC6.3 cells 
Previous study showed that the antioxidants Sod2 and Trx2 in cells are regulated by NF-κB 
signaling (Kairisalo et al., 2007). To study the involvement of NF-κB signaling in the antioxidant 
effects of Sig-1R in PC6.3 cells, we determined the levels of NF-κB-p65 (p65, RelA) protein that is 
important for NF-κB signaling (Hayden and Ghosh, 2004). Treatment of the cells with PRE084 was 
able to restore the NF-κB-p65 levels that were downregulated by mHTT (II/Fig.5A-B). Using a NF-
κB luciferase reporter construct we showed that NF-κB activity was decreased in cells expressing 
mHTT (75Q), whereas the wt HTT (17Q) had no effect. Most importantly, treatment with PRE084 
prevented the decrease in NF-κB activity in mHTT (75Q) expressing cells (II/Fig.5C). The 
activation of NF-kB by PRE084 may underlie the beneficial effects of this compound in oxidative 
stress.  
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PRE084 and overexpression Sig1-R elevate calpastatin in mHTT expressing cells 
Previous study has shown that calpastatin is decreased and the activity of calpain is elevated in cells 
expressing the 120Q-huntingtin-fragment protein. Calpastatin functions as an inhibitor of calpain   
(Reijonen et al., 2010). Calpains are proteolytic enzymes activated by increased cell calcium and are 
involved in the regulation of oxidative stress and other processes in the cell (Harwood et al., 2005). 
The results showed that stimulation of the PC6.3 cells with PRE084 increased the calpastatin levels 
that are reduced by overexpressing mHTT (120Q) (II/Fig.6A-B). The increase in calpastatin by 
PRE084 was accompanied by a reduced calpain activity as shown by decreased cleavage of the 
calpain substrate, α-spectrin (II/Fig.6C). 
 
Figure 12. Summarizing figure.   
 
To study whether PRE084 elevated calpastatin in control cells, we stimulated cells with the 
compound for up to 24h. Data showed that calpastatin levels were significantly induced by PRE084 
at 24 h and that overexpression of Sig-1R had the same effect (II/Fig.6D-E). To reveal whether 
calpastatin mRNA levels were also increased by PRE084, we performed qPCR that showed no 
change in calpastatin expression following PRE084 treatment (II/Fig.6F). This suggests that the 
PRE084 may primarily influence the stability or the degradation of calpastain in protein level. 
This study identified a signaling pathway mediating neuroprotection in cells expressing mHTT 
involving the calpastatin/NF-κB signaling pathway. PRE084 counteracted the deleterious effects of 
mHTT in neuronal PC6.3 cells by increasing calpastatin and by activating NF-κB signaling which 
increased antioxidant levels and reduced ROS. The findings are summarized in Figure 12. 
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5.3 Ubiquitin specific protease-14 (Usp14) protects against mutant huntingtin-
induced cell degeneration and reduces cellular aggregates (III) 
Autophagy and the UPS are the two main degradation pathways in the cell. It has been thought 
before that degradation of mHTT by the proteasome is unwieldy and that aggregates are subjected 
to degradation by autophagy. However it has been shown that inhibiting the UPS leads to a greater 
accumulation of mHTT than inhibiting autophagy (Li et al., 2010). This has led to a suggestion that 
the clearance of soluble N-terminal mHTT is more dependent on the function of the UPS. Also, 
since the proteasomes are present in the nucleus, the UPS function may be more important for 
clearing nuclear aggregates. Autophagy might function as a backup system to clear mHTT and is 
more efficient to remove the aggregated forms of mHTT (Li et al., 2010). Although it is clear that 
the UPS is important for clearing mHTT, it remains unclear whether HD affects the capacity of 
neuronal UPS to remove toxic and misfolded proteins (Li and Li, 2011). 
Studies of HD mouse models have provided evidence that the extent of protein misfolding and 
aggregation is correlated with the length of polyQ tract and that smaller N-terminal HTT fragments 
containing an expanded polyQ tract are more prone to misfolding and aggregation. They are also 
more toxic than FL mHTT, which is evident by the fact that cellular models expressing smaller HTT 
fragments show more aggregates than those expressing FL mHTT (Gutekunst et al., 1999; Hackam 
et al., 2000). The aggregates contain ubiquitin and part of the HD pathophysiology could result from 
an imbalance in cellular ubiquitin levels (de Pril et al., 2004). Deubiquitinating enzymes are 
important for replenishing the ubiquitin pool but little is known about their roles in HD.  
Overexpression of mHTT induces ER stress and activation of ER signaling pathways (Reijonen et 
al., 2008; Vidal et al., 2011). Mutant HTT also impairs the ERAD pathway (Duennwald and 
Lindquist, 2008; Yang et al., 2010).  
5.3.1 Usp14 levels are unchanged but Usp14 is redistributed in mutant huntingtin 
expressing cells 
Usp14 is an important DUB in the nervous system and we reasoned that it could be involved in 
neurodegenerative diseases caused by disturbed protein metabolism. We studied the Usp14 levels in 
neuronal PC6.3 cells after expression of HTT fragment proteins linked to EGFP having different 
polyQ repeats (18Q, 39Q, 53Q, 120Q). There was no overt change in the total cellular levels of 
Usp14 as observed by immunoblotting and immunohistochemistry (III/Fig.1A-B).  
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To study whether the distribution of Usp14 in the cells might change we performed cell 
fractionation studies using PC6.3 control cells, 18Q and 120Q huntingtin fragment proteins. Data 
showed that the amount of Usp14 associated with the ER membrane fraction substantially decreased 
in mHTT expressing cells whereas the level of Usp14 increased in the cytosolic fraction (III/Fig.1C-
D). This indicates that the subcellular localization of Usp14 is altered in mHTT cells. Apart from its 
association with the ER, USP14 is also localized to proteasomes and specifically binds the 
proteasome 19S subunit S2 as shown by an immunoprecipitation assay for Usp14 using control and 
mHTT stably expressing HeLa cells (III/Fig.1E). Data showed that the binding of Usp14 to 19S S2 
were roughly the same in cells expressing wt and mHTT, suggesting that Usp14 binds the 
proteasome also in mHTT expressing cells.  
5.3.2 Overexpression of Usp14 reduces cellular aggregates in mHTT expressing cells 
mainly via the ubiquitin proteasome system 
As observed before, expression of the 120Q HTT fragment protein produces aggregates both in the 
nucleus and cytoplasm in neuronal PC6.3 cells (Reijonen et al., 2008). Accumulation of mHTT 
aggregates in the cell is a balance between their synthesis and degradation, involving the autophagy 
and/or the UPS. We noticed that overexpression of Usp14 decreased the amount of aggregates in 
mHTT expressing cells. We counted the number of aggregates from confocal images of 18Q and 
120Q-huntingtin expressing PC6.3 cells in the absence or presence of Usp14 co-expression and 
performed a solubility assay (III/Fig.2A-C). Usp14 overexpression reduced SDS-insoluble 
aggregates in 120Q-huntingtin expressing PC6.3 cells as shown by the western blot analysis of the 
SDS-soluble and insoluble samples.  
Usp14 seemed to reduce mHTT aggregates mainly via the UPS. Mutant HTT expressing cells were 
treated with 20 μM MG-132 (a proteasome inhibitor) for 8 h and 5 mM 3-methyladenine (an 
autophagy inhibitor) for 4 h. The inhibitors, per se, had no significant effect on the number of cells 
with aggregates. However, when the UPS was inhibited, Usp14 overexpression did not reduce the 
amount of aggregates as it did without inhibition. Also inhibiting the UPS lead to a greater 
accumulation of aggregates than inhibiting autophagy after Usp14 overexpression (III/Fig.2D). 
Using mutant, enzymatically inactive, Usp14 construct, we observed that the reduction of 
aggregates required the intact DUBs domain (III/Fig.2E).  
Although the autophagy inhibitor 3-MA increased the cell aggregates in mHTT expressing cells, the 
effect was not statictically significant (III/Fig.2D). These results indicate that the Usp14-mediated 
decrease of mHTT aggregates largely involves the UPS and less so the autophagy system. Mutant 
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HTT aggregates contained ubiquitin as shown by the confocal images of cells transfected with GFP-
ubiquitin and flHTT (17Q and 75Q). Data showed that ubiquitin was present throughout the cell in 
wt HTT expressing cells (17Q) but accumulated in the aggregates in cells expressing mHTT (75Q) 
(III/Fig.2F). 
To examine the function of Usp14 further, we used stably mHTT expressing HeLa cells in our 
studies (Filimonenko et al., 2010). These tetracycline-regulatable HeLa cells stably express the first 
17 amino acids of HTT followed by a polyQ expansion (65Q or 103Q) tagged to monomeric CFP 
(HttPolyQ-mCFP). Doxycyclin (dox) can be used to shut off production of new HTT protein in 
these cells.  To analyze aggregate clearance, HeLa cells were treated with dox, which led to 
inclusion clearance over several days in a macroautophagy- dependent manner (Yamamoto et al., 
2006). Our data showed that inhibition of Usp14 or its activity did not influence the dox-mediated 
clearance of mHTT further indicating that Usp14 mainly affects the UPS in the aggregate clearance 
(III/Fig.3A). 
We also studied the interaction of Usp14 with the mHTT aggregates by performing 
immunoprecipitation experiments. Data showed that Usp14 binds both wt and mHTT (III/Fig.3F) 
5.3.3 IRE1α, involved in ER stress response, is activated in mHTT expressing cells as 
well as in the striatum of mHTT transgenic (BAC-HD) mouse 
We and others have shown that the expression of mHTT induces ER stress by activating different 
ER signaling pathways such as the IRE1 pathway (Reijonen et al., 2010). Interestingly, previous 
data suggest that Usp14 interacts with IRE1 and influences ERAD (Nagai et al., 2009). However, 
nothing has been known about the role of Usp14 in mHTT induced ER stress and cell death. We 
therefore studied whether the reduced ER membrane association of Usp14 in mHTT expressing 
cells (III/Fig.1C-D) is reflected by a decreased binding of Usp14 to IRE1α. Immunoprecipitation 
experiments, with tissue lysates from BAC-HD mice, showed that Usp14 binds IRE1α in cells 
expressing wtHTT, but less so in mHTT expressing cells (III/Fig.5A) Immunostaining further 
showed that Usp114 is partly co-localized with IRE1α in wt, but not mHTT, expressing cells 
(III/Fig.5B).  
To study whether the decreased binding of Usp14 influences the activation of IRE1α, we performed 
WB experiments. Overexpression of Usp14 was able to inhibit phosphorylation of IRE1α in mHTT 
overexpressing cells (III/Fig.5C-D).  
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The change in Usp14 and IRE1α was also observed in brain samples obtained from BAC-HD mice. 
IRE1α was activated in the striatum but not in brain cortex of BAC-HD mice compared with 
respective controls (III/Fig.6).  We also observed that the binding of Usp14 to IRE1α was less 
prominent in samples from BAC-HD striatum than in wt controls (III/Fig.6).  
5.3.4 Overexpression of Usp14 protected against cell degeneration and caspase-3 
activation induced by mHTT  
Knowing that Usp14 binds to IRE1 in unstressed cells and dissociates in stressed conditions, we 
wanted to study if overexpression of Usp14 could protect cells against mHTT triggered ER stress 
and cell death. For this purpose we co-transfected neuronal PC6.3 cells with huntingtin and Usp14 
plasmids. Overexpression of Usp14 significantly decreased cell death and increased cell survival in 
mHTT expressing cells (III/Fig4.A-C) Overexpression of Usp14 inhibited the cleavage of caspase-3 
and PARP. Usp14 also reduced the number of cells with chromatin condensation and fragmentation 
(III/Fig.4C). 
 
Figure 13. Summarizing figure.  
 
Usp14 might have a dual role in neuroprotection by trimming the ubiquitin chains in the protein 
aggregates and thus rendering them accessible for the proteasome and by reducing IRE1α 
phosphorylation and ER stress in cells expressing mHTT. Hence, Usp14 can be a potential target to 
consider in developing novel therapeutics for HD and other aggregate disorders.  
Our results showed that ER stress induced IRE1 activation is part of mHTT toxicity which is 
inhibited by Usp14. Usp14 effectively reduced cellular aggregates and counteracted cell 
degeneration indicating its important role in mHTT induced cell toxicity. The results are 
summarized in Figure 13.  
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6 CONCLUSIONS AND FUTURE PROSPECTS 
Since the identification of the gene and mutation responsible for the disease two decades ago, the 
field of HD has been the focus of intense research (The Huntington's Disease Collaborative 
Research Group, 1993). Important advances have been made, but still the precise 
pathophysiological mechanisms of HD are poorly understood. There is no cure for HD and currently 
there are only symptomatic drugs available for treating the illness.  
Both a loss-of-function of wtHTT and a toxic gain-of-function of mHTT are thought to contribute to 
HD pathology, promoting the activation of proteases, protein misfolding, inhibition of protein 
degradation, transcription deregulation, autophagy dysfunction, metabolic and mitochondrial 
disruption, and oxidative stress, which over the years culminate in neurodegeneration (Gil and Rego, 
2008)  
Some of the pathological changes mentioned above were investigated in this thesis work. The 
studies clarified how ER stress, alterations in autophagy and in ubiquitin proteasome system and 
oxidative stress are involved in the early pathological processes in HD. The experiments were 
mainly carried out using cellular models of HD, PC6.3 and HeLa expressing HTT constructs with 
different polyQ stretches. PC6.3 cells are known to be useful and valid models for characterizing 
cellular and molecular events in cell death. However, further studies, executed in in vivo animal 
models and eventually in HD patients, will be needed in future.  
Alterations in autophagy have been proposed to contribute to pathogenesis in HD, but the precise 
mechanism behind autophagy malfunction is poorly understood. This thesis work unraveled that 
GADD34 is involved in autophagy regulation in cellular model of HD (I). Our results demonstrated 
that the mTOR pathway is downregulated and autophagy is induced in neuronal PC6.3 cells at 24 h 
after expression of mHTT. TSC complex interacted with GADD34, which caused TSC2 
dephosphorylation and induction of autophagy in mHTT expressing cells. However, GADD34 
protein levels and autophagy decreased at later time points, 48 h after transfection with the 
concomitant increase in mTOR activity. By overexpressing GADD34 we were able to induce 
autophagy in mHTT expressing cells. GADD34 induced autophagy served as a protective signal 
against the deleterious effects of mHTT and thus was cytoprotective. In view of neuroprotective 
effects of GADD34, it may be a useful target to consider in defining novel therapeutic strategies for 
HD and other neurodegenerative diseases.  
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It remains to be studied whether GADD34 has other protein targets, in addition to PP1 and TSC 
complex that are active during cell stress and neurodegeneration. Another interesting prospect to 
study in future is the role of mHTT induced ER stress in mTOR-independent autophagy. mTOR has 
many vital cellular functions like regulation of translation and cell growth, and therefore, it is highly 
desirable to discover mTOR-independent, autophagy-inducing pathways or drugs as therapeutic 
targets.  
The present work also identified a signaling pathway mediating neuroprotection in cells expressing 
mHTT, involving the Sig-1R, its agonist PRE084, and the calpastatin/NF-κB signaling pathway (II). 
The beneficial effect of the Sig-1R agonist PRE084 was observed both in cells expressing the N-
terminal mHTT-fragment protein (120Q) and the FL mHTT protein (75Q). The mechanism by 
which PRE084 induced neuroprotection was ascribed to the restoration of the calpastatin and NF-
κB-p65 levels, which then upregulated various cellular antioxidants and decreased ROS levels with 
a positive effect on cell survival. Our data indicated that PRE084 and other compounds influencing 
Sig-1R may constitute promising targets for the development of hopefully more effective 
therapeutic strategies for HD. However the next step would be to study whether PRE084, or other 
Sig-1R agonists, have neuroprotective effects in other experimental models of HD. Several 
compounds with agonistic activities at Sig-1R are already approved for clinical use and seem to be 
well tolerated (Francardo et al., 2014).  
This thesis revealed new interesting data about the involvement of the deubiquitinating enzyme, 
Usp14, and proteasome function in HD (III). HTT aggregates contain ubiquitin and part of the HD 
pathophysiology has been thought to result from inhibition of proteasomal function, but very little is 
known about the functions of deubiquitinating enzymes in HD. Our results showed that Usp14 
enhanced proteasome-mediated clearance of mHTT aggregates and acted as a link between mHTT-
induced ER stress induction and the enhanced neuronal degeneration. We further showed that 
overexpression of Usp14 was able to counteract cell death in mHTT expressing cells. We also 
observed that IRE1α, acting as an ER stress sensor, was preferentially activated in the striatum of 
BACHD mice. Along with this, the interaction of Usp14 with IRE1α was reduced in the ER 
membrane in mHTT expressing cells and in the striatum of BACHD mice. The precise mechanisms 
regulating the Usp14-IRE1α interaction and its role in protein quality control in the ER remains to 
be studied in more detail in the future.  
The role of Usp14 in protein degradation is controversial. Some studies suggest that Usp14 plays an 
inhibitory role in protein degradation and some studies have shown that Usp14 induces protein 
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degradation. A study showed that overexpression of Usp14 inhibited the ER-associated degradation 
(ERAD) pathway, and Usp14 depletion by siRNA effectively activated ERAD (Nagai et al., 2009). 
A more recent study showed that Usp14 removes ubiquitin chains from I-κB, therefore inducing I-
κB degradation (Mialki et al., 2013). In our study, we considered that the cleavage of the ubiquitin 
chain by Usp14 could render the mHTT aggregates more accessible for degradation via the 
proteasomes. It remains to be studied whether the same strategy involving increased cleavage of 
ubiquitin chains from protein aggregates may be beneficial in other neurodegenerative diseases as 
well.  
In recent years, our understanding of the dynamic aspect of ubiquitin modifications has increased 
significantly.  We have realized that DUBs have equal prominence than the ubiquitin ligases. In 
addition to UPS, DUBs also have roles in the endocytic and ERAD pathways. In future it is 
important to study their role in proteasomal degradation and autophagy in more detail. It would also 
be interesting to study how Usp14 affects ERAD and autophagy in HD.  
HD can be regarded as a model neurodegenerative disease as it is monogenic and similar to several 
other neurodegenerative disorders. Thus, research in HD may convey information about the early 
intervention strategies relevant also to other neurodegenerative diseases like Parkinson’s disease and 
Alzheimer’s disease. Current animal models replicate insufficiently the selective striatal cell death 
of human HD, so better disease models, both in vivo and cellular models, are needed. Induced 
pluripotent stem cells and other patient-derived cell models could be good alternatives for future 
modeling of the disease. 
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